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ABSTRACT
Inflammatory bowel diseases (IBD), mainly ulcerative colitis (UC), Crohn’s disease
(CD), are chronic, idiopathic, inflammatory diseases of the gastrointestinal tract affecting
millions of people worldwide. The incidence of IBD is steadily increasing in the modern
world due to changes in dietary habits and other environmental influences that originated
from industrialization. The etiology is poorly understood but is believed to be a
combination of genetic predisposition, environmental factors, and overactive immune
system. UC is characterized by inflammation and ulceration of colonic mucosa and rectum
and has a higher incidence than CD. Aside from severely affecting the quality of life of the
patients, IBD also increases the risk of developing colorectal cancer (CRC). Hence, it is
imperative to find a treatment that not only treats colitis but can also act as a
chemopreventive agent. Current medications that include aminosalicylates, TNFα
inhibitors, and corticosteroids help patients cope with the symptoms and induce temporary
remission, but are paired with a risk of serious side effects and people become refractory.
Many patients, therefore, turn to unconventional treatments for relief and plant-based
products provide a safe, alternative option.
Many studies have shown that American Ginseng (AG), an herb native to North
America is effective in the treatment of diabetes, cancer, cardiovascular diseases, and
neurodegenerative diseases. Our lab has previously shown that AG treats colitis and
prevents colon cancer in mice. This indicates the potential for AG to become part of
mainstream medicine like other drugs that have natural antecedents, e.g., taxol, vincristine,

vi

digoxin, etc. Drug discovery from plant products involves phytochemical and biological
characterization of plants used in alternative medicine. This dissertation aims to address
these issues by identifying the bioactive component of AG and elucidating the mechanism
of action in the treatment of UC and prevention of CRC.
We used bioassay-guided fractionation to identify the most potent fraction of AG. A
hexane fraction of AG (HAG) has shown remarkable anti-inflammatory and anti-cancer
properties both in vitro and in vivo. Sub-fractionation of HAG revealed that Panaxynol
(PA), a polyacetylene is the most abundant compound in this fraction and also showed antiinflammatory potential in vitro as indicated by suppression of iNOS, an inflammation
marker. PA effectively suppressed DSS induced colitis in mice and showed potential as a
chemopreventive agent. PA targets macrophages (mФ) for DNA damage and apoptosis
while it requires >10X dosage to sustain cause similar effects in other cell types.
AG has been shown to decrease oxidative stress and Nuclear factor (erythroidderived 2)-like 2 (NFE2L2 or Nrf2)-a transcription factor that is a master regulator of
antioxidant response), we hypothesized that AG, HAG, and PA treat colitis by activating
the Nrf2 pathway. AG, HAG, and PA decreased oxidative stress and activated the Nrf2
pathway in vitro and in vivo. Accordingly, in vivo experiments indicate that AG, HAG, and
PA were not very effective in the treatment of DSS induced colitis in Nrf2 knockout mice.
We further delineated the mechanism of action of AG in the absence of inflammation
using gene expression profiling of primary peritoneal mФ by microarray. We found that
AG and its compounds showed distinct immunomodulatory properties, as shown by the
activation of both pro-inflammatory cytokines and anti-inflammatory molecules. These
results will bring AG a step closer to being used as a conventional drug for the treatment
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of colitis and pave the way for its use in the treatment of other inflammatory and
autoimmune diseases with a similar genesis.
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CHAPTER 1
INTRODUCTION
1.1 GENERAL OVERVIEW
Inflammation is the immune system’s first line of defense against foreign pathogens
or, irritants. Inflammation protects the body against infection and injury by choreographing
an immune response involving immune cells and cytokines, to eliminate the pathogens
and/or repair the tissue damage (1,2). The important elements of this response include
vasodilation to facilitate immune cell filtration and release of cytokines and chemokines
that elicit an appropriate pro or anti-inflammatory response. The infiltration of
inflammatory cells like macrophages (mФ) and neutrophils can elicit physical symptoms
of pain, redness, and swelling (1). These inflammatory cells release cytokines like nitric
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and activate signaling cascades
involving nuclear factor kappa-light-chain-enhancer of activated B cells (NFκb) and tumor
necrosis factor (TNF) α, which can eliminate the invading pathogens and repair the tissue
damage (2–4).
A genetic predisposition and environmental factors contribute to an overactive
immune system and associated chronic inflammation. The chronic and cyclical
inflammation associated with autoimmunity can drive tumorigenesis (5).

More

specifically, chronic inflammation in the affected tissue increases cancer risk in that tissue.
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Patients with IBD (UC and CD) have an increased risk of CRC (6). Studying the
molecular mechanisms has led to biological therapies including TNF-α inhibitors.
However, overall treatment outcomes in IBD patients have been modest, people become
refractory, and there are side effects. Therefore, approximately half of all patients turn to
complementary and alternative medicines.
Complementary and Alternative Medicines (CAMs) that includes dietary and
medicinal supplements like curcumin, grapes, garlic, ginseng, etc., are being explored as
potential treatments with minimal side effects (7–9). A number of natural products have
been assimilated into the mainstream medicine for the treatment of various diseases.
However, CAMs such as plants, herbs, and spices are an amalgam of multiple compounds,
and it is important to isolate a single, potent component that might be useful as a
standardized stand-alone treatment, or in a standardized natural cocktail for the suppression
of colitis. Mechanisms are also addressable, where this is more difficult with complicated
mixtures making up natural mixtures. The general low toxicity of plant constituents make
them candidates for long-term use and therefore the prevention of CRC. Over the past
several years, our lab has shown that AG can treat UC and prevent CRC in mice. This
project aims at identifying the bioactive component in AG and delineating the mechanism
of action of AG and its derivatives.
1.2 ULCERATIVE COLITIS
IBDs are chronic, inflammatory, idiopathic diseases that can affect the entire
gastrointestinal (GI) tract (CD) or just the colon (UC) (10). IBD incidence has been
increasing since the mid-20th century, indicating the effects of the changing lifestyle and
dietary habits, including smoking, diets high in fats and sugar, medication, and stress (10).
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UC has a higher incidence than CD with a rate of 10.2 to 20.3 cases per 100,000 per year
and a prevalence of 7.6 to 246 cases per 100,000 per year. In the USA, this translates to 1.4
million people affected (10). The etiology of this disease is unclear but is believed to be
multifactorial, with genetics, immunological, and environmental (alterations in the
epithelial barrier, infection, microflora composition, nutrition, stress, etc.) factors playing
an important role (11). The genetic predispositions can affect the interaction of the immune
system with microbial and other environmental factors, leading to a disruption in the gut
homeostasis and this causes an abnormally high proinflammatory response towards the
commensal bacteria (12).
Colitis manifests mainly in patients between ages 15-30, but might have a
secondary peak between the ages of 50-70 and is characterized by inflammation of the
mucosal layer of the large intestine(13). The clinical symptoms include diarrhea, often with
blood or pus, abdominal pain and cramping, rectal bleeding and pain, the urgency to
defecate and inability to defecate despite the urgency, weight loss, dehydration,
tachycardia, anemia, fatigue, and fever (14). Additionally, there are some extraintestinal
manifestations of IBD in children and adolescents, which can lead to delayed growth and
changes in cognitive and sexual development (14). Colitis also has a detrimental effect on
the quality of life for the patients due to its chronic, recurring nature. However, the most
important and extreme consequence of colitis is the increased risk of CRC. The chronic
inflammatory state of the disease makes an ideal environment for tumorigenesis, and the
risk of developing CRC increases with the length of disease, with long-term patients facing
20% risk (12). CRC is the second leading cause of cancer deaths with the prediction of up
to 50,000 deaths per year (12). Scheduled colonoscopies in colitis patients act as good
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preventative strategy, but it needs to be paired with potent treatments, which can act as
chemopreventive agents.
1.2.1 IMMUNE CELLS IN THE INTESTINE
The organs with high interaction with the extraneous environment like lungs and
intestines have additional layers of defenses from the immune system (15,16). The mucosal
barrier in the intestines, along with the epithelial layer forms the first line of defense against
the microorganisms and contains the immune cells (neutrophils, monocytes, mФs,
dendritic cells, natural killer cells, eosinophils, and basophils) responsible for the innate
immunity (17)(18). These immune cells sample the antigens and elicit an appropriate
response, which is often short-lived (18). Dendritic cells and mФs in the intestines, along
with the epithelial cells and myofibroblasts, sense conserved molecular patterns on
microbes known as pathogen-associated molecular patterns (PAMPs), via pattern
recognition receptors (PRRs) encoded in the germline (18). This engagement results in the
initiation of an inflammatory response involving the release of inflammatory cytokines,
chemokines, and antimicrobial peptides(19). This further leads to the phagocytosis of
infected cells and pathogens, followed by antigen presentation by dendritic cells to the Tcells, thereby activating the adaptive immunity (20). The adaptive immune system
comprises of B-cells and T-cells, which produce antibodies and cytokines, respectively
(21).
In the intestine, which faces a constant exposure to a wide array of antigens in food,
it is important to maintain tolerance to the symbiotic bacteria while also protecting from
enteric pathogens by eliciting an immune response when needed. Any disturbance in this
homeostasis can lead to pathogenic diseases like CD and UC (22).

4

1.2.2 MACROPHAGES
MФs and dendritic cells belong to myeloid lineage along with neutrophils,
differentiate from monocytes (23). Monocytes are produced in the bone marrow and are
abundant in lymph nodes and spleen (24). In the case of an invading pathogen, monocytes
migrate to the site of infection or damage through the bloodstream and mature into mФs
through a series of complex differentiation events that require the presence of interleukins
(IL-1, IL-32, and IL-6) (25–27). Upon their discovery, the main function of mФs was
thought to be phagocytosis which is essential for wound healing and clearance of
microorganisms (28). Later, the other main function of mФs, pro-inflammatory cytokine
production, was identified and is responsible for the initiation of adaptive immunogenic
response and when left unchecked, leads to prolonged inflammation (29).
MФ are a diverse group of cells and can be categorized based on their location and
function into different types, M1 and M2 being the two main categories (30). M1 mФ are
pro-inflammatory and are considered classically activated or polarized mФ. M1 mФ
mainly secrete cytokines and protect the host from invading microorganisms and have antitumorigenic properties (31). M1 mФ can be activated by interferon-γ (IFN-γ) (secreted by
helper T-cells (Th1), cytotoxic T cells (Tc), NK cells and mФ themselves) or
lipopolysaccharides (LPS) (secreted by bacteria) (32). M1 mФ also enhance the Th1
response and this response, in turn, enhances the activity of mФs (33). M1 mФ are
characterized by increased glycolic rate and reduced mitochondrial oxidative
phosphorylation when compared to the M2 mФs (34). M1 mФs secrete cytokines such as
IL-1β, tumor necrosis factor (TNF) α, IL-12, IL-18, and IL-23 (31). MФs can also increase
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the production of nitric oxide from L-arginine, by activating nitric oxide synthase (iNOS),
resulting in a cytotoxic activity towards various intracellular and extracellular intruders
such as bacteria, fungi, helminths, viruses, and tumor cells (35). In case of inflammatory
diseases, M1 mФs are shown to be responsible for the initiation and sustenance of
inflammation (36).
M2 mФ (alternatively activated mФ) and are considered anti-inflammatory with
regenerative properties. M2 mФ are activated as a part of the Th2 response, by IL-4, IL13, IL-10, and transforming growth factor (TGF)-β (36). They are involved in tissue
homeostasis and repair, and have a higher metabolism and are characterized by the
secretion of high amounts of IL-10 and low levels of IL-12 (37). M2 mФ also produce
matrix metalloproteases and growth factors to aid in the wound healing (38).
The mФ in the lamina propria (LP mФs), also known as the resident mФ, are largely
anti-inflammatory. They have microbicidal activity and clear microbes and other stimuli
that cross the epithelial barrier (39). However, they do not produce any pro-inflammatory
cytokines (40). On the contrary, they support the transition from inflammatory to the antiinflammatory environment (40). Inappropriate responses from mФ to the gut microbiota
has been shown to play an important role in the pathogenesis of colitis (41). Enhanced proinflammatory response from the mФs releases nitric oxide (NO), and increases the
oxidative stress that not only results in the disruption of the epithelial barrier, but also
subcellular and molecular damage to macromolecules like DNA, RNA, protein, lipids,
metabolites, etc., thereby contributing to the initiation and maintenance of the disease (42).
Continued intracellular damage is one of the main causes of transition into colorectal
cancer.
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1.2.3 OXIDATIVE STRESS IN ULCERATIVE COLITIS
An imbalance between the production of free radicals and reactive metabolites, and
their elimination results in oxidative stress, one of the hallmarks of inflammation (43). This
imbalance could lead to the damage of important biomolecules and various signaling
pathways, resulting in a negative impact on the organism (42). Inflammation can induce
and exacerbate oxidative stress in multiple ways. During chronic inflammation,
inflammatory cells that are recruited to the site of damage. This recruitment leads to a
respiratory burst as a result of increased uptake of oxygen, thereby causing an increased
accumulation of ROS at the site (44). Inflammatory cells also secrete cytokines like
interleukins, tumor necrosis factor (TNF) α, and interferon (IFN) γ and chemokines like
CX3-type chemokine receptor (CX3CR) 1, which can, in turn, stimulate the production of
ROS and RNS (45). For example, TNF-α enhances the formation of ROS by neutrophils
and other cells, while interleukin-1-β (IL-1-β), TNF-α and IFN-γ stimulate the expression
of inducible nitric oxide synthase (iNOS) in inflammatory and epithelial cells.
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) comprise the
main reactive intermediates, and the antioxidants encompass the protective mechanisms
responsible for their elimination of these metabolites. ROS are generated by the
mitochondrial respiratory chain as a part of cellular metabolism and play an important role
in the alteration of signaling pathways in cells in response to changes in intracellular and
extracellular environmental conditions (46). When cells are subjected to prolonged
environmental stress, and ROS are produced over a long period, it results in significant
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damage to cell structure and also induces somatic mutations that can result in the neoplastic
transformation of the cells (47). RNS are generated from NO, which is synthesized by
iNOS, usually after a challenge by immunological or inflammatory stimuli (48). RNS
increase the risk of mutagenesis by further generating other reactive species, e.g., reactive
aldehydes-malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), by inducing
excessive lipid peroxidation (49). Oxidative stress plays thus an important role in the
initiation and progression of tumorigenesis by increasing DNA mutations or inducing DNA
damage, genome instability, and cell proliferation. H2O2 is a less reactive but important
type of ROS that is formed from superoxide anion (O2-) or spontaneously in peroxisomes
from molecular oxygen. H2O2 can react with reduced transition metals like Fe+ to produce
hydroxyl radical (·OH), which in turn can cause DNA damage (50).
It is important to note that low or moderate levels of free radicals act as a defense
mechanism against infectious agents by triggering the protective, antioxidant systems and
signaling pathways. There are multiple endogenous antioxidant systems in place that are
triggered and regulated by different metabolites. Glutathione reductase (GR), superoxide
dismutases (SODs), and catalase are the important enzymatic antioxidants that can combat
and scavenge the free radicals that can cause oxidative stress (51,52). On the other spectrum
of antioxidant defense are the various transcription factors like AP1, CREB, HSF1, HIF-1,
TP53, NF-κB, Notch, SP1, and CREB-1 (53). Of these, the Nrf2 (nuclear factor erythroid
2 [NF-E2]-related factor2)-Keap1 (Kelch-like ECH-associated protein-1) signaling
pathway, involving the transcription factor, Nrf2, is one of the important regulators of cell’s
protective responses to oxidative stress (54).
1.2.4 NRF2
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The transcription factor, Nrf2 attenuates inflammation by combating oxidative and
xenobiotic stresses via the activation of multiple antioxidant genes like heme oxygenase 1
(HO-1) and NAD(P)H Quinone Dehydrogenase 1 (NQO1) (55). HO1 catalyzes the
degradation of heme and NQO1 catalyzes the reduction of quinones to hydroquinones
thereby causing detoxification of quinones (56). Nrf2 also controls the expression of
enzymes involved in the production of glutathione (GSH), the most important antioxidant
cofactor in cells (56,57).
Nrf2 has an extremely short half-life (~15 minutes) resulting in a rapid turnover
and a slightly longer half-life of ~30 minutes when induced (58). The activity of Nrf2 is
mainly regulated by Keap-1. Keap-1 is a substrate for a ubiquitin-ligase complex, and by
sequestering Nrf2, it mediates the proteasomal degradation of Nrf2 (58). Conformational
changes in the Keap-1 protein can free Nrf2, which can translocate into the nucleus and
perform its function as a transcriptional factor (58). These conformational changes can
occur in multiple ways, e.g., ROS can induce the oxidation of cysteine residues or some
proteins like p62 and p21 can disrupt the binding of Nrf2 to Keap-1, thereby causing the
activation of the Nrf2 pathway (58). Upon translocation, Nrf2 can bind to the cis-acting
enhancer antioxidant response element (ARE; core sequence: TGAG/CNNNGC) on
promoters of the target genes (59). The promoter region of Nrf2 also has two ARE regions
which it can bind to and auto-regulate the activation (60).
The importance of Nrf2 in the alleviation of inflammatory diseases is demonstrated
in various murine models. Deficiency of Nrf2 in mice resulted in exacerbation of
inflammation in emphysema, pleurisy, and sepsis (61–64). Furthermore, activation of Nrf2
in myeloid cells resulted in an anti-inflammatory response. Recently, a Nrf2 inducer,
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Tecfidera, has been approved for the treatment of multiple sclerosis, an autoimmune
disorder (65). This suggests that Nrf2 activation can be used as a treatment strategy for
various inflammatory diseases like colitis.
1.2.5 CURRENT TREATMENTS
Prolonged inflammation of colitis, when left untreated, can lead to hemorrhage,
toxic dilation, perforation, and death (12). Various treatments are available for the
treatment of colitis, depending on the severity of the disease and stage. NSAIDs like
aspirin, sulindac, and ibuprofen are used to treat the symptoms of pain and inflammation
for mild flares (12). NSAIDs act by interfering with cyclooxygenase (COX) pathways and
are not selective towards either of the two isoforms, COX1 and COX2 (12). COX1 is a
housekeeping gene that plays an important role in cytoprotection by producing
prostaglandins in various tissues like stomach, duodenum, and kidneys (66). While COX1
is constitutively expressed in these tissues, COX2 is almost undetectable in normal
conditions and is induced during inflammation to reach 200-300 times the basal levels (66).
NSAIDs have adverse effects like mucosal damage and nephrotoxicity with prolonged use
due to their lack of selectivity (67).
Moderate flares require steroids which suppress the hyperactive immune system or
anti-inflammatory drugs like 5-aminosalicylic acid (5-ASA) (68). Severe attacks,
especially in pediatric patients, require inpatient treatment with intravenous corticosteroids
and two-thirds of colitis cases may require a colectomy (68). While steroids are effective
in a short-term use, long-term intake is associated with multiple side effects, like a low rate
of mucosal healing. 5-ASA is an anti-oxidant that is often ineffective and requires longterm use to achieve remission (14)(68).
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More recently, biologics like adalimumab (Humira), certolizumab (Cimzia),
infliximab (Remicade) and natalizumab (Tysabri) are being used to inhibit inflammation
(68). The first three biologics mentioned target TNFα, and the fourth targets α4-integrin, a
cell adhesion molecule (69). However, these biologics, especially the TNFα inhibitors have
dangerous side effects like increased risk of infections (e.g., tuberculosis) due to suppressed
immune function (69). Due to the ineffective nature of current treatments, paired with
dangerous side effects, it is imperative to find a novel, safe, and effective treatment.
Approximately 50% of patients turn to alternative treatments like acupressure,
homeopathy, and Tai Chi for solace (70,71). There has also been an increased use of natural
products like flax seeds, aloe vera, and garlic. Here, we have tested another natural product,
American ginseng, for its use as an alternative therapy for colitis.
1.3 AMERICAN GINSENG
Ginseng root has been used for centuries in traditional medicine for various
ailments and general well-being. The botanical name of ginseng, Panax, means ‘allhealing’ and is closely related to the Greek word ‘panacea.' Ginseng is a mixture of many
components that include saponins, polyacetylenes, ginseng oils and phytosterol,
carbohydrates and sugars, organic acids, nitrogenous substances, amino acids and peptides,
vitamins and minerals, and certain enzymes (72). Among these, saponins (also known as
ginsenosides) and polyacetylenes have shown to be the active ingredients and have been
extensively studied for the treatment of multiple diseases including cancer, diabetes, and
various inflammatory and cardiovascular diseases. Ginseng use is also intended for overall
health with beneficial effects on immune, cardiovascular, nervous and endocrine systems.
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Various species of ginseng are cultivated all over the world; Asian, Korean, or
Chinese Ginseng (Panax ginseng), notoginseng (Panax notoginseng), and American
ginseng (Panax quinquefolius) are the most commonly studied species of ginseng. These
different species of Ginseng vary in their chemical composition, e.g., ginsenosides Rf and
R1 are present in Korean ginseng and notoginseng but not American ginseng, which
exclusively contains pseudoginsenoside F11 (73). Furthermore, the ratio of Rg1/Rb1 can be
used for differentiation between the different species; ratios less than 0.4 indicate American
ginseng while higher ratios indicate Korean or notoginseng (74). Korean ginseng has been
used extensively in traditional medicine in Asia for thousands of years while American
ginseng has been gaining popularity in the Western world in the recent decades for its wide
range of pharmacological properties. Whole American ginseng root extract and its
chemical components have been examined as potential treatments. More recently, different
parts of this plant like fruit, leaves, and flowers are being studied not only for physical
ailments but also, mental health, general well-being, and cosmetological benefits.
Like most medicinal plants, American ginseng (AG) has antioxidant properties due
to which it is effective in the treatment of various diseases where free radicals, like reactive
oxygen and nitrogen species, contribute to the pathogenesis of the disease. AG can protect
cardiomyocytes from injury and prevent heart disease by scavenging hydrogen peroxide
and hydroxyl radicals. AG also decreases oxidative stress in the central nervous system
(CNS), thereby contributing to the prevention of memory loss. AG has been shown to have
a hepatoprotective effect by increasing the activity of major antioxidant enzymes, GSH-Px
(glutathione peroxidase) and SOD (superoxide dismutase). AG has also been shown to
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prevent myocardial injury and neurodegeneration by inhibiting various ion channels (Ca+,
K+, Na+, etc.) in a stereospecific manner.
1.3.1 AMERICAN GINSENG FOR THE TREATMENT OF COLITIS AND COLON CANCER
In the past few years, our lab and Dr. Chong-Zhi Wang’s lab at the University of
Chicago have done separate and parallel studies to explore the potential of AG as a
treatment for colon cancer (75–84). However, we have focused on investigating AG as a
treatment for UC and specifically, colitis-induced colon cancer while the research in Dr.
Wang’s lab concentrated AG’s effect on the different types of colon cancer. Our studies,
however, have undeniably complemented one another. Here, I will summarize findings
from both groups to highlight the significance of AG as a prospective treatment for colitis
and colon cancer.
AG has significant anti-inflammatory effects in vitro and in vivo. Incubation of
ANA-1 mФ with AG, followed by activation with IFN-g (polarizes ANA1 cells into
proinflammatory M1 type) results in decreased activation of iNOS, eNOS, NO release and
I-kB, oxidative burst and oxidative stress. Preincubation of HT-29 colon cells with AG
prevents DNA damage from cytokine-induced inflammatory stress when exposed to M1
type ANA1 cells. AG mimicked these effects in vivo – aside from suppressing the
proinflammatory markers mentioned above, AG treatment of DSS treated mice also
decreased the number of CD+ cells such as T helper cells, monocytes, mФs, and dendritic
cells in the inflamed colon. One of the mechanisms of action of AG is p53 dependent – AG
does not cause apoptosis in p53-/- inflammatory cells (NH32) and is not effective in the
prevention of colitis in p53-/- mice (79,84).
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We have shown AG decreases the number of macroscopic lesions and the severity
of microscopic adenomas in an AOM-DSS induced colon cancer model. Upon further
investigation using protein arrays, it was shown that AG decreases the expression or
activation of tumor-promoting genes like c-Jun, Pax 2 and ErbB2, while it increases the
expression of tumor suppressors like PP6C, EphA1, and IRAK1 (80). Others have shown
that AG attenuates colon cancer in different mouse models – AOM and western (high fat)
diet-induced colon cancer in A/J mice, high-fat diet induced colon cancer in ApcMin-/+ mice
(85,86). Treatment of mice with AG in these models increased the phosphorylation of
EGFR, ERK and AKT and also Bax, which is consistent with increased apoptosis (85).
More recently, it has been shown that AG also altered the metabolomics and microbiota
profiles in the AOM/DSS-induced colitis and colon carcinogenesis models. These profiles
in the AG treatment groups are closer to the water control groups indicating that AG can
alter the effects that inflammation can have on the microbiota (87).
1.3.2 FRACTIONATION OF AMERICAN GINSENG
Our lab used bioassay-guided fractionation to obtain multiple fractions American
Ginseng and tested their anti-inflammatory properties to identify the most potent ingredient
in AG. AG was sequentially partitioned against various solvents (hexane, dichloromethane,
ethyl acetate, water, and methanol) each containing a different composition of active and
inactive chemical entities. The Hexane fraction of AG (HAG) appeared to be the most
potent one as evidenced by its ability to suppress iNOS and COX-2 expression in
proinflammatory (M1) ANA-1 mФ and its cytotoxic effects on RAW264.7 cells (88,89).
Furthermore, HAG also caused apoptosis of inflammatory cells in a manner comparable to
the whole AG extract in vitro and in vivo (88). HAG also suppressed DSS-induced colitis,
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and AOM-DSS induced colon cancer in mice further confirming that HAG contains the
active ingredient/s responsible for similar effects by AG (88,90). However, the effects of
HAG can only be partially attributed to p53. HAG caused apoptosis in p53-/- cells, even
though the effect was significantly lower when compared to cells with wild-type p53.
Similarly, HAG suppressed DSS-induced colitis in both p53 wild-type and p53 knockout
mice, with better effects in the wild-type mice.
Global microRNA (miRNA) comparison of HAG treated HCT-116 colon cancer
cells with untreated cells showed increased expression of Mir-29b by HAG. Mir29b
suppresses matrix metalloproteinase-2 (MMP-2), thereby suppressing migration of colon
cancer cells, indicating a potential for HAG and AG in the suppression of metastasis (81).
Upon establishing the effectiveness of HAG as a potential fraction containing the bioactive
ingredient of AG, we further fractionated HAG, and identified Panaxynol (PA) (also
known as falcarinol and carotatoxin), to be the most abundant ingredient.
1.3.3 PANAXYNOL
PA is a polyacetylene found in common food and medicinal plants belonging to
Apiaceae (e.g., carrots, celery, parsnip, etc.) and Araliaceae (e.g., AG, ivy, etc.)
families(91). Polyacetylenes are a distinct group of molecules found in medicinal plants
and have been recognized to have numerous pharmacological properties. PA was initially
considered a dietary toxin (hence the name, carotatoxin) due to its pro-allergenic effects
that are responsible for contact dermatitis from common ivy (92). However, the
concentration of PA in vegetables and roots is lower, and when combined with
desensitizing effect of oral intake, the risk of an allergic reaction is low (91). More recently,
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PA is being studied as a potential medicinal drug due to its anti-cancer, anti-inflammatory,
antimicrobial and neuroprotective properties.
The anti-cancer effects of PA are evidenced by its antiproliferative and cytotoxic
effects towards various cancer cell lines such as; leukemia (L-1210), human gastric
adenocarcinoma (MK-1), mouse melanoma (B-16), renal carcinoma cells (A498, Caki-1,
and CURC I), and mouse fibroblast-derived tumor cells (L-929) (93–97). However, it is
not clear how it compares with cytotoxicity towards normal cells as there is conflicting
data in this regard and appears to depend on the cell lines tested rather than the cell type
(91,95,98). It is interesting to note that the effect of PA is biphasic in intestinal cells (Caco2), where it increased the cell proliferation at doses lower than 10 μM but apoptosis at
doses higher than 20 μM (99). This biphasic effect conforms to the consensus that toxicity
is dose-dependent and toxic compounds can have beneficial effects at lower
concentrations. However, the anti-cancer effect of PA in vivo has not been extensively
studied. PA from carrots decreased the number of azoxymethane (AOM)-induced preneoplastic lesions in rats and dehydrofalcarinol, a secondary metabolite of PA have been
shown to have a modest effect on tumors induced in a LOX melanoma mouse xenograft
model (100,101).
The mechanism of action of PA has not been elucidated but studies indicate the
DNA alkylating potential of PA (99), and one of the signaling pathways that could be
affected is MAP kinase pathway, where PA has been shown to inhibit the phosphorylation
of ERK1/2 and CREB (102).
1.4 DSS MOUSE MODEL OF COLITIS
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DSS induced colitis is one of the most widely used models to study UC in mice.
The effect of DSS is limited to the mouse colon and is very similar to that of human colitis
in etiology, pathology, and clinical outcome (103). The DSS treatment can be manipulated
to achieve the different types of inflammation (103). For example, treatment with DSS for
1-2 weeks mimics acute inflammation while treatment with DSS in alternative weeks for
multiple cycles represents chronic inflammation. We treated mice with DSS before or after
treating the mice with PA to check the effectiveness of PA as a treatment and preventative
for colitis respectively.
The precise mechanism of action of DSS is unknown but the sequence of events,
where crypt loss precedes inflammation, suggest that DSS affects the epithelial layer and
increases permeability (103). There are multiple theories proposed to explain the mode of
insult to the epithelium by DSS. DSS affects the permeability by disrupting the tight
junction protein (Zona occulens-1) (104) between the cells or the negatively charged
sulfate groups in DSS can damage negatively-charged (anionic phospholipids) cell
membranes by repulsive forces (105). This increased permeability increases the bacterial
infiltration thereby causing an inflammatory response (105). It is also believed that the
anticoagulant nature of DSS increases the intestinal bleeding further exacerbating the
disease (105). However, the molecular weight of DSS plays an important role in
determining the severity and extent of colitis, with 35000-50000 being the most effective
range for inducing colitis (106).
1.5 OBJECTIVES OF THE RESEARCH
As discussed earlier, current medications are ineffective in the treatment of colitis and are
accompanied by a horde of dangerous side effects. In order to find a natural and effective
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treatment, we have previously tested AG and shown that it successfully suppresses colitis
in mice. A natural next step is to identify the bioactive component of AG so that it can be
used as a conventional treatment for colitis. The objective of this research is two-fold –
1. To identify the bioactive component of AG (Figure 1.1) and
2. To elucidate the mechanism of action of AG and its components in the treatment of
colitis (Figure 1.2).
To this end, the following conclusions have been reached:
Conclusion 1: PA, a bioactive component isolated from AG, is effective in the treatment
of DSS induced colitis in mice (Chapter 2)
Conclusion 2: PA specifically targets mФ for DNA damage and apoptosis. (Chapter 2)
Conclusion 3: Activation of the Nrf2 pathway is essential for the treatment of colitis by
AG, HAG, and PA. (Chapter 3)
To further elucidate the pathways influenced by the action of AG and its
components, we performed gene expression profiling of primary mФ treated by AG and
identified the potential targets.
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Figure 1.1. Schematic for the identification of a bioactive component of American
Ginseng. Bioassay-guided fractionation determined that Hexane fraction of AG was found
to be the most potent fraction of AG, of which Panaxynol was the most abundant molecule.
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Figure 1.2 Schematic for mechanisms of action of AG and its components. Confirmed
and potential mechanisms of action of AG, HAG, and PA in the treatment of UC, other
inflammatory diseases, and cancer. The solid blue line represents previously confirmed
mechanisms, solid green lines represent mechanisms confirmed in this dissertation, and
dotted orange lines indicate potential mechanisms.
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CHAPTER 2
PANAXYNOL, A BIOACTIVE COMPONENT OF AMERICAN
GINSENG, TARGETS MACROPHAGES AND SUPPRESSES
COLITIS IN MICE
ABSTRACT
Ulcerative colitis (UC) has a significant impact on the quality of life for the patients,
and can substantially increase the risk of colon cancer in patients suffering long-term.
Conventional treatments provide only modest relief paired with a high risk of side effects,
while complementary and alternative medicines can offer safe and effective options. Over
the past decade, we have shown that American ginseng, particularly the hexane fraction of
American ginseng (AG), has anti-oxidant and anti-inflammatory properties that can
suppress mouse colitis and prevent colon cancer associated with colitis. With the goal of
isolating a single active compound, we further fractionated the hexane fraction, and found
the most abundant molecule in this fraction was the polyacetylene, Panaxynol (PA). After
isolating and characterizing PA, we tested the efficacy of PA in the treatment and
prevention of colitis in mice and studied the mechanism of action. We demonstrate here
that PA effectively treats colitis in a Dextran Sulfate Sodium mouse model by targeting
macrophages (mФ) for DNA damage and apoptosis. Positive outcomes from this study will
take American ginseng one-step further towards becoming a conventional drug for the
treatment of colitis, possibly other autoimmune diseases associated with macrophage
dysfunction, and for the prevention of inflammation-driven carcinogenesis.
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2.1 INTRODUCTION
Inflammatory bowel diseases (IBDs), including UC and Crohn’s disease (CD), are
debilitating, significantly affect lifestyle, and carry a high colon cancer risk. IBD
prevalence is particularly high in North America and Europe (affecting 3.8 million people),
with an economic burden of $30 - $45 billion (1–4). Of note, incidence has been increasing
for both males and females over the past 20 years (5), making this a health problem that
needs to be addressed for both sexes. As a frustration to patients with IBD, conventional
treatment outcomes are modest, e.g., 20% do not respond to anti-TNFα antagonists (6), and
toxicity leads to dangerous side effects. As such, about half of all IBD patients (millions)
turn to complementary and alternative medicines (CAMs). Although CAMs have been
used for thousands of years, there is a gap in our knowledge of the mechanisms that support
their effectiveness. Understanding these mechanisms will not only lead to standardized and
more efficient treatment for IBD outside of toxic FDA-approved drugs but will also better
our understanding of the potential applications of CAMs for other diseases with similar
mechanisms.
The natural herb, American ginseng (Panax quinquefolius; AG), improves mental
performance and detrimental endpoints associated with diseases, such as cardiovascular
disease, diabetes, and influenza (7,8). Over the past decade, we have shown that AG has
anti-oxidant and anti-inflammatory properties and can suppress mouse colitis and prevent
colon cancer associated with colitis (9–11). Using bioassay-guided fractionation, more
recently, we have shown that a hexane fraction of AG (HAG) was particularly potent in
this capacity (12–14).
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With a goal of isolating a single, bioactive compound from AG and HAG, we further
fractionated HAG and found that the most abundant molecule in this fraction was the
polyacetylene, PA. Polyacetylenes are a distinct group of naturally occurring products,
whose numerous pharmacological properties have been recognized (15). PA ([3(R)-(9Z)heptadeca-1, 9-dien-4, 6-diyn-3-ol]; falcarinol) is a bioactive member of this family. It has
been identified in both traditional herbal medicines (such as AG), and in common dietary
plants, e.g., carrots, celery, fennel, parsley, and parsnip (16). Interestingly, PA has been
shown to have anti-cancer properties (16–19) and neuroprotective effects (20–22).
However, there remains an unanswered question regarding PA’s potential as an antiinflammatory molecule and, therefore, its capacity to suppress chronic inflammatory
diseases, such as UC. Intriguingly, PA (as compared to the hundreds of other potential
CAMs currently used with success in animals) not only comes from a natural source, but
is a single molecule, allowing the potential to be standardized on its own, or in a cocktail.
What makes this molecule innovative is the putative mechanism we explore here by
addressing the hypothesis that PA targets mФ for apoptosis resulting in the suppression of
colitis in mice.
2.2. MATERIALS AND METHODS
2.2.1 IDENTIFICATION AND ISOLATION OF PANAXYNOL
Characterization of HAG and extraction of PA were carried out by our collaborator,
Dr. Anthony Windust at the National Research Council (Ottawa, ON, Canada). The method
for characterization and analysis of HAG has been described in detail previously [12].
Briefly, for characterization of bioactive components of HAG, this fraction was subfractionated through preparative, reverse-phase HPLC, where the HAG was divided into
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five sub-fractions based on elution time (4 minutes each). The fractions were collected over
six repeat runs (6 x 50 mg injected) and evaporated to dryness. A comparative analysis by
analytical scale LC-UV of both the whole and each sub-fraction was performed to confirm
identities of constituents in each sub-fraction.
PA was isolated and purified from Panax quinquefolius grown on the Harper Ranch,
Kamloops, BC, Canada. The method of extraction and purification of PA has been
previously described (23). Briefly, dried root of 4-year-old AG was dissolved in ethanol,
and the organic layer was concentrated using vacuum centrifuge to yield dark brown oil.
This extract was further separated using flash chromatography, and the fractions containing
PA were dried to yield crude PA. The crude PA was then subjected to multiple passes of
chromatography, and the purity of the final extract was validated using liquid
chromatography with UV diode array detection (LC-UV-DAD). Purified PA was dissolved
in 95% ethanol for use in in vitro and in vivo experiments.
2.2.2 CELL LINES AND REAGENTS
All cells were maintained in appropriate media recommended by ATCC
supplemented with 10% New Born Calf serum (NBCS) (Biofluids, Rockville, MD),
penicillin (10 U/ml) and streptomycin (10 μg/ml, Biofluids) at 37°C in a humidified
chamber with 5% CO2 atmosphere. Experiments with PA were carried out by treating the
cells with indicated concentrations of PA dissolved in appropriate media with 0.1% NBCS.
For polarization to M1 type mФ, ANA-1 cells were exposed to 10 ng/ml interferon-γ
(IFNγ) for 8 hours (R&D Systems, Minneapolis, MN) either before or after the treatment
with PA. For differentiation of U-937 monocytes into mФ, cells were treated with 10 ng/ml
phorbol 12-myristate 13-acetate (PMA) (Sigma; P1585) for 24 hours. After replacing with
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fresh media containing no PMA, the cells were allowed to grow for 48 hours before
treatment with PA. CD4+CD25- cells were isolated from the spleens of C57BL/6 mice as
previously described [13]. Briefly, the mФ and B cells were depleted before isolation of
CD4+CD25- T cells using MACS separator along with CD4 and CD25 microbeads
(Miltenyi Biotec, Auburn, CA). For co-culture experiments, HCT-116 cells were plated in
6-well dishes and ANA-1 mФ activated with IFN-γ were placed in the inserts (2018-11,
Grenier bio-one; Kremsmünster, Austria) to mimic an inflammatory environment.
2.2.3 WESTERN BLOT ANALYSIS AND ANTIBODIES
Phospho-Histone H2AX (Ser139) (cat # 9718S), phosphor-p53 (Ser15) (cat #
9284S), and GAPDH (cat # D16H11) (5174S) rabbit monoclonal primary antibodies
(1:1000 dilution); and horseradish peroxidase conjugated anti-rabbit secondary antibody
(7074S) (1:2000 dilution) were purchased from Cell Signaling Technology, Danvers, MA.
Primary antibody incubations were carried out overnight at 40C Secondary antibody
incubations were carried out at room temperature for 1 hour. The Western blot signal was
detected by Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL) and
developed onto Hyperfilm (GE Healthcare Life Sciences, Pittsburgh, PA) or imaged using
Bio-Rad ChemiDoc Imager.
2.2.4 FLOW-CYTOMETRIC TUNEL ANALYSIS
TUNEL labeling was performed using Fluorescein in situ cell death detection (cat
# 11684795910, Roche Diagnostics, IN). Briefly, cells were incubated in 0.1% NBCS
supplemented media containing appropriate concentrations of PA or vehicle. Cells were
harvested after 12 hours of treatment, and TUNEL assay was performed as described by
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the vendor. TUNEL positive cells were detected and quantified using Beckman Coulter
F500 Flow Cytometer and CXP software.
2.2.5 IN VIVO EXPERIMENTS
DSS (MW 36000–50000) obtained from International Laboratories USA (San
Francisco, CA) was used to induce colitis in mice. 8-10 week old C57BL/6 mice were
obtained from Jackson Laboratories (Bar Harbor, ME) and maintained in a suitable
environment according to the Institutional Animal Care and Use Committee (IUCUC)
standards. The care and usage of the mice were monitored by Animal Resource Facility
(ARF) at the University of South Carolina, Columbia. This study was approved by IACUC
(Animal Use Protocol # 2178).
For the prevention model of colitis, mice were given PA, once daily, at different
doses (0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg and 1 mg/kg diluted in ddH2O) by oral gavage
for two weeks. The lowest dose was calculated based on our previous experiments with
AG and HAG. The PA dose was equated to reflect the percentage composition of PA in
HAG. Mice were given 2% DSS in drinking water to induce colitis starting on day 7. For
the colitis treatment experiments, mice were given 2% DSS in their water for two weeks.
Starting on day 7, mice were given PA at the same doses as the prevention experiments
(0.01 mg/kg, 0.1 mg/kg, 0.5 mg/kg and 1mg/kg; Table 2.1) by oral gavage. Control mice
were given ddH2O by oral gavage. The weight of mice was monitored over the duration of
the experiment. The mice were sacrificed on day 14 and colons were harvested, length was
measured and processed for further analysis.
For macrophage depletion, we administered 200 μl clodronate liposomes in PBS
via intraperitoneal injection (i.p.) and empty liposomes in PBS were used as a vehicle
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control. The first injection was on the day -1 with the subsequent injections on days 2, 6,
10 and 13. DSS was administered starting on day 0 through day 13, and PA treatment was
given days 7-13. Mice were sacrificed on day 14.
Blood in stool was detected using Hemoccult (Beckman Coulter) fecal
immunochemical test. Immediately before sacrifice, stool consistency (0-fully formed
stool; 2-loose stool; 4-diarrhea) and blood in the stool (0-no blood; 2-detected using
Hemoccult; 4-rectal bleeding) were scored, and these measurements were used along with
the weight difference in mice from the beginning to the end of the experiment (0=no weight
loss; 1= 0-5% weight loss; 2= 6-10% weight loss; 3=11-15% weight loss; 4=16-20%
weight loss), to calculate the CDI.
2.2.6 INFLAMMATION SCORING
Paraffin-embedded colons were serially sectioned (5 µm), and one section from each
mouse was stained with hematoxylin and eosin. The stained slides were blindly examined
under a microscope by two investigators (A. Chaparala and A. Chumanevich) for
histopathological changes and scored according to a system previously described and
extensively used by our lab and many others (12,24,25). Briefly, the histology score for
inflammation accounts for four parameters – 1) inflammation severity (0 (no
inflammation), 1 (minimal), 2 (moderate), and 3 (severe)); 2) inflammation extent (0 (no
inflammation), 1 (mucosa only), 2 (mucosa and submucosa), and 3 (transmural)); 3) crypt
damage (0 (no crypt damage), 1 (one-third of crypt damaged), 2 (two-thirds damaged), 3
(crypts lost and surface epithelium intact), and 4 (crypts lost and surface epithelium lost))
and; 4) percentage area of involvement (0 (0% involvement), 1 (1-25%), 2 (26-50%), 3
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(51-75%), and 4 (76-100%)). The scores for the first three parameters are added and the
sum is multiplied by the fourth parameter, giving a range of scores between 0-40.
2.2.7 IMMUNOHISTOCHEMISTRY
Sections of paraffin-embedded colons were incubated with cyclooxygenase-2 (COX-2)
(cat # 60126; Cayman Chemical Company, Ann Arbor, MI) CD11b (cat # ab133357;
Abcam, Cambridge, UK) mouse polyclonal antibody, diluted 1:10,000 in Antibody
Amplifier™ (ProHisto, LLC, Columbia, SC) overnight. The slides were then processed
using EnVision+ System HRP kits (DAKO, Carpinteria, CA) according to the instructions
provided by the kit, which uses the chromagen, diaminobenzidine to elicit dark brown
reaction to the HRP-tagged secondary antibody provided in the kit. Methyl green was used
as a secondary stain. Immunoreactivity score was obtained by multiplying scores from two
criteria – 1) percentage of tissue stained (0-5: 0 (0% positive staining), 1 ( < 10%), 2 (1125%), 3 (26%-50%), 4 (51%-80%), or 5 ( > 80%)), and 2) staining intensity (0-3: 0
(Negative staining), 1 (Weak), 2 (Moderate), or 3 (Strong)). The scores of two parameters
are multiplied, giving a range of scores between 0-15.
2.2.8 STATISTICAL ANALYSIS
Data are expressed as a mean ± standard error of the mean. Mean differences
between the groups were compared by one-way analysis of variance (ANOVA), followed
by Dunnett’s multiple comparison tests. A P-value of ≤ 0.05 was chosen for significance.
2.3 RESULTS
2.3.1 PANAXYNOL IS THE MOST ABUNDANT AND POTENT ANTI-INFLAMMATORY MOLECULE
IN AG

We have previously shown that AG and HAG are effective in the treatment of colitis

36

and prevention of colon cancer (9–14). We have also demonstrated that fatty acids and
polyacetylenes are both components in AG and HAG (12). In moving forward, to better
understand the active components of HAG, we have sub-fractionated this fraction of AG
(Fig 2.1A). Sub-fraction 1 (F1; <10% of the whole HAG) contains multiple minor
components including two minor polyacetylenes tentatively identified based on UV spectra
(Fig 2.1B). F2 (30% of HAG) contains two major polyacetylenes, Panaxadiol and
Panaxydol, and four minor polyacetylenes tentatively identified based on UV spectra (Fig
2.1C). F3 (24% of HAG) contains a major polyacetylene, PA, and a fatty acid, linolenic
acid (18:3n3) (Fig 2.1D). F4 (27% of HAG) contains linoleic acid and no detectable
polyacetylenes (Fig 2.1E). F5 (10%) contains minor fatty acids including saturates, and no
polyacetylenes (Fig 2.1F). F2 and F3, the only fractions containing major polyacetylenes,
suppress iNOS induction in ANA-1 mФ polarized to the M1 type with IFNγ (Fig 2.1G),
which is predictive of colitis suppression (10,12). Of the three major polyacetylenes in F2
and F3 sub-fractions of HAG, PA was the most abundant (10.2%) (12); therefore, we
proceeded to test its efficacy as an anti-inflammatory compound.
2.3.2 PANAXYNOL IS EFFECTIVE AS A TREATMENT FOR COLITIS IN DSS MOUSE MODEL
Following the isolation of PA from HAG, and an initial screening (iNOS
suppression in vitro [23]), we tested the efficacy of this compound in the prevention and
treatment of DSS-induced mouse colitis. In the prevention model, where mice were treated
with PA for a week before the induction of colitis using DSS (Fig S1A), treatment with PA
did not inhibit colitis in mice when compared to the control group. Moreover, there was a
marginal increase in the inflammation score with the highest dose of PA (Fig 2.8 A, B)
when compared to the vehicle group, indicating that pre-treatment with PA slightly

37

exacerbated DSS-induced colitis. Although we are currently exploring the possible
mechanism of this finding, it appears caution has to be made when considering PA for any
chemoprevention purposes.
Excitingly, PA was very effective in the treatment model of colitis (Fig 2.7 1B),
where colitis was induced with DSS for a week followed by PA treatment. PA significantly
decreased the Clinical Disease Index (CDI) (Fig 2.2E) and the inflammation score (Fig
2.2A, B) in a dose-dependent manner. Colonic inflammation from PA-treated mice was
limited to the distal end of the colon, while in the vehicle group, inflammation involved a
larger area. To examine a biomarker of inflammation, we tested each colon section for
cyclooxygenase-2 (COX-2) immunoreactivity. There was a decreased expression of COX2 with PA treatment (Fig 2.2C, D). When taken together, the results are consistent with the
hypothesis that PA can be used to treat mouse colitis. To note, we monitored the weights
of the mice over the course of the experiment and did not observe any unexpected weight
loss even with the highest dose of PA, indicating the non-toxic nature of PA.
2.3.3 PANAXYNOL TARGETS MACROPHAGES FOR DNA DAMAGE IN VITRO
In an effort to identify the mechanism of action of PA, we studied the structure and
observed that PA is a hydrophobic compound with several sites of potential modification
that could convert it to a DNA reactive alkylating agent (Fig 2.9). The hydroxide at the 3position (C3) can be converted to a α, ß unsaturated aldehyde, which is a Michael acceptor,
while the double bond between the 9 and 10 position could potentially be converted to an
epoxide. Furthermore, the hydroxide group on C3 can react with the amino group of nucleic
acids and alkylate DNA. We, therefore, screened multiple cell types for PA-induced DNA
damage. Strikingly, PA caused DNA damage, as identified by γ-H2AX expression.
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However, γ-H2AX induction only occurred in mФ. These included mouse mФ (ANA-1,
Fig 3A, B; RAW264.7, Fig 3C), primary peritoneal mouse mФ (Fig 3D), and human mФ
(U-937, Fig 2.3E). For all non-macrophage cells (Fig 3F-K), γ-H2AX induction was not
seen up to 10 µM PA treatment. As well, when U-937 human monocytes were not
differentiated to mФ, γ-H2AX induction was also not seen until 10 µM PA treatment (Fig
3K) when compared to induction at 1 μM in U-937 cells differentiated into mФ (Fig 2.3E).
This indicated the specificity of DNA damage to mature mФ and not monocytes. PA also
induced phosphorylation of p53 at Ser15 in ANA-1 cells, further confirming DNA damage
(Fig 2.10).
2.3.4 PANAXYNOL SELECTIVELY TARGETS MACROPHAGES

FOR APOPTOSIS IN VITRO AND IN

VIVO.

Based on the understanding that DNA damage is associated with apoptosis, we
hypothesized that PA could selectively cause apoptosis in mФ. Results are consistent with
this hypothesis in two macrophage cell lines (Fig2. 4A – C). Apoptosis was minimal in
other non-macrophage cells, including HCT-116 cells (Fig 2.4D) and mouse embryonic
fibroblasts (MEFs) (Fig 2.4E). To examine whether PA selectively causes apoptosis in mФ
in the presence of other cell types, we carried out a co-culture experiment with ANA-1 mФ
and colon cancer cells (HCT-116). Figure 4F shows that PA causes apoptosis in ANA-1
mФ at significantly higher levels than in HCT-116 cells. This property of PA would
distinguish it from broadly immunosuppressive drugs that are currently on the market for
the treatment of UC.
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2.3.5 PANAXYNOL TARGETS MACROPHAGES FOR APOPTOSIS IN VIVO
To confirm that PA targets mФ in vivo, we used colons from the DSS-induced
colitis experiment to perform IHC for mФ. We used a CD11b antibody, which is a surface
marker for mФ and we saw that PA-treated colons have lower expression of CD11b when
compared to the vehicle group, indicating that PA treatment decreased the number of mФ
in vivo (Fig 2.2A, B).
We also conducted a DSS-colitis mouse experiment with clodronate, a compound
that can deplete mФ. We administered clodronate before treatment with DSS to deplete
mФ and treated them with PA after inducing colitis with DSS. Macrophage depletion with
clodronate decreased the intensity of colitis, but we did not see any synergistic effect with
PA treatment. Interestingly, PA was more effective than clodronate treatment for the
amelioration of colitis as evidenced by the changes in inflammation score (Fig 2.5 C, D).
2.4 DISCUSSION
Currently available treatments for UC have multiple side effects and affect major
organs like kidneys, liver (hepatitis), and pancreas (pancreatitis) (26). Furthermore,
immune targeting drugs, e.g., infliximab that targets the TNF pathway, are broadly
immunosuppressive thereby weakening the immune system, and making the body more
susceptible to other infections like tuberculosis. We have shown that AG treats colitis in
mice; however, it is composed of multiple ingredients with diverse effects, making it unfit
for use as a mainstream drug. Upon examining the different extracts of AG, we identified
HAG to be the most effective fraction in the treatment of colitis. Further analysis examined
the various components of HAG. PA, apart from being the most abundant molecule in
HAG, is also more effective than the whole HAG in suppressing iNOS expression in mФ
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that are polarized to M1 (pro-inflammatory) type. Hence, testing PA for the treatment of
colitis is a natural step towards the identification of the bioactive component to treat colitis
and prevent colon cancer.
Consistent with our previous studies with AG and UC, we used DSS-induced mouse
colitis model for studying the effect of PA on an inflammatory disease. We found that PA
treats DSS-induced colitis in the mouse, as seen by decreased CDI, inflammation, COX-2
expression, and the halted weight loss in treated mice. There was no toxicity even at higher
doses, as observed by the insignificant weight changes. In future experiments, we will
examine the effect of PA on liver and kidneys to rule out possible toxicity.
One of the mechanisms by which AG and HAG treat colitis is by targeting immune
cells for apoptosis (11,13). We also examined the structure of PA and identified it to be a
hydrophobic compound, is a potential DNA-reactive alkylating agent. PA and its
derivative, falcarindiol, have previously been shown to be protein-alkylating agents (27).
Furthermore, it has been shown that PA causes DNA damage in CaCo2 cells (28). It can
be reasoned that the mechanism of action of PA can be via the induction of DNA damage.
Our preliminary results show that PA causes DNA damage in multiple cell lines and that
mФ are especially sensitive to DNA damage induced by PA. We predict that one possible
anti-inflammatory mechanism of action of PA is targeting mФ for DNA damage and
apoptosis. This is an interesting finding with this property being unique to PA.
Furthermore, we also show that mФ are more sensitive to apoptosis by PA. We also saw
in our preliminary experiments that treatment with Panaxynol increases the
phosphorylation of p53 at Ser15 (Fig. S4). This indicates activation of p53 as a result of
DNA damage and the activated p53 can then induce apoptosis or cause growth arrest. In
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this case, p53 is possibly causing activation of apoptosis pathway. This further indicates
that γ-H2AX was possibly induced because of DNA damage, and not the disintegration of
DNA resulting from apoptosis.
PA, however, did not prevent colitis in mice. Furthermore, treatment with the highest
dose of PA slightly increased the inflammation score when compared to the untreated mice.
The resident mФ in the lamina propria of the intestine are anti-inflammatory and important
for the maintenance of homeostasis. They clear any microbes and other stimuli that cross
the epithelial cell barrier, mainly by phagocytosis, but do not secrete any cytokines (29).
Since PA targeted mФ before induction of colitis in the prevention model, the disease was
more severe, and PA was ineffective. This is consistent with previous studies that showed
that depletion of mФ before induction of colitis resulted in exacerbated DSS-induced colitis
(30). However, upon initiation of UC, there is increased accumulation of proinflammatory
mФ that secrete cytokines to enhance the inflammatory response. An overactive response
by the mФ to the enteric microbiota at this stage greatly contributes to the pathogenesis of
colitis (31). Treatment with PA to target mФ at this stage was highly effective in
suppressing colitis.
The reason for the mФ being specifically targeted by PA is not completely understood.
Future directions will explore the mechanisms of DNA damage and a possible defect in
DNA repair. Investigating whether PA can prevent colon cancer is the next natural step, as
macrophage depletion not only decreases inflammation but also suppresses tumorigenesis
in AOM-DSS-induced model of colitis induced colon cancer in mice (32). PA is effective
in the treatment of colitis and does so by targeting mФ for DNA damage and apoptosis.
We have tested a range of doses (0.01 mg/kg – 1 mg/kg), and demonstrate that PA is very
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effective at 0.1 mg/kg, which would translate to 6 mg for an average patient weighing 60
kg. This is an extremely low dose when compared to the immunosuppressive drugs
currently available, placing PA a step above the other treatments for UC.
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Figure 2.1. Isolation and characterization of various sub-fractions of HAG. A-F) LCUV/DAD analysis of Hexane fraction and each sub-fraction. F1 to F5 represent the
collected fractions, 4 minutes each. Peak identities: Panaxadiol (1), Panaxydol (2), PA (3),
linolenic acid (4), linoleic acid (5) Column C-18 2.1 x 100 mm, 1 µl injection of a 5 mg
mL-1 (whole) or equivalent fraction, gradient 55% to 90% acetonitrile/water in 15 minutes;
hold 5 minutes; re-equilibration 10 minutes. Note: The scale magnification for subfractions 1 and 5 is 2X. G) Effect of HAG and different sub-fractions of HAG on IFNγinduced iNOS expression. ANA-1 mouse mФ were incubated for 12 hours with HAG or
the indicated sub-fractions (10 µg/ml), washed, then exposed to IFNγ (10 ng/ml) for 0, 2,
and 4 hours. C+ indicates the positive control, which is ANA-1 cells induced by IFNγ, and
then incubated with media.
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Figure 2.2. Panaxynol suppresses DSS-induced colitis in mice. A) Representative
images (magnification – 100X) of histological sections from 3 groups; water, DSS only
and highest dose of PA (1 mg/kg/day). B) Inflammation scores obtained from H & E slides
of the colon cross-sections. C) Representative images of sections stained for COX-2
(magnification – 400X). D) Immunoreactivity score (IRS) of COX-2 from IHC staining.
E) Clinical Disease Index (CDI) accounts for weight loss, blood in stool and stool
consistency (n=8). Values represent mean ± SEM. One-way ANOVA followed by
Dunnett’s test was used for comparison between samples. p-value when compared to DSS
group is indicated by: * = <0.05, ** = <0.01, *** = <0.001, **** = <0.0001.
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Figure 2.3. Panaxynol induces γ-H2AX in macrophages, but not in other cell types.
All cell types were treated with PA at specified doses for 12 hours. Activated mФ were
generated by treating with IFNγ (10 ng/ml for 8 hours) before PA treatment. U-937 cells
were treated with 10 ng/ml PMA for 24 hours for differentiation into mФ. Nuclear protein
extract from HCT116 cells overexpressing Flag-tagged γ-H2AX was used as a positive
control for γ-H2AX. A-E) MФ showed increased DNA damage with doses starting from 1
µM, as shown by the increase in the expression of γ-H2AX, a sensitive marker of DNA
damage. F-J) Non-macrophage cell lines, including other immune cells (i.e., lymphoblasts
and T cells) and epithelial cell lines, did not show any change in the protein expression of
γ-H2AX and K) U-937 cells which are monocytes were more sensitive than U-937 mФ.
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Figure 2.4 Panaxynol induces apoptosis in macrophages, but not in HCT-116 and
MEF cells. Cells were treated with PA for 12 hours with indicated doses. PA significantly
increased the percentage of apoptotic cells in A) unstimulated ANA-1 cells at 50 µM (18%)
and 100 µM (70%), B) IFNγ stimulated ANA-1 cells at 10 µM (3.3%) and C) RAW264.7
cells at 50 µM (50%) and 100 µM (99%). D) PA had no significant apoptotic effect on
HCT-116. E) PA induced apoptosis in MEFs only at a high dose of 100 µM (9.5%).F) In
a co-culture experiment, PA caused apoptosis only in ANA-1 cells, but not HCT-116 cells.
p-value indicated by; * = <0.05, ** = <0.01, *** = <0.001, **** = <0.0001.
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Figure 2.5 Panaxynol targets macrophages in vivo. Effect of PA on macrophages in vivo.
A) Representative images of sections stained for CD11b (magnification – 400X) (N=8). B)
Immunoreactivity score (IRS) of CD11b from IHC staining. C, D) DSS mice were treated
in the presence and absence of clodronate (which depletes macrophages) to assess the
involvement of macrophages in the treatment by PA. C) CDI). C) Clinical Disease Index
(CDI) accounts for weight loss, blood in stool and stool consistency (n=6-8). D)
Inflammation scores obtained from H & E slides of the colon cross-sections. Values
represent mean ± SEM. One-way ANOVA followed by Dunnett’s test was used for
comparison between samples. p-value when compared to DSS group is indicated by: * =
<0.05, ** = <0.01, *** = <0.001, **** = <0.0001.
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Figure 2.6 Schematic of the mechanism of action of Panaxynol. PA targets macrophages
for DNA damage and apoptosis, thereby decreasing the inflammation and treating UC in
mice.
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SUPPLEMENTAL FIGURES FOR CHAPTER 2

C)

Figure 2.7: Schematics of in vivo experimental courses. A) Prevention model of colitis
where the mice were treated with PA before induction of colitis using 2% DSS. B)
Treatment model where mice were treated with PA after the manifestation of the disease
due to DSS treatment. C) Clodronate experiment model where mice were treated with
clodronate liposomes intermittently as indicated.
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Table 2.1 Treatments and conditions for each group. n = 8
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Figure 2.8: Panaxynol does not prevent colitis in mice. A) Representative images of H
& E stained sections of colons (100X). B) Inflammation scores obtained from H & E
slides of the colon cross-sections.

52

Figure 2.9: Structure of Panaxynol
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Figure 2.10: Treatment with Panaxynol increases the phosphorylation of p53 at
Ser15 in ANA-1 cells. ANA-1 cells were treated with 10ng/ml IFNγ for 8 hours for
activation of M1 type mФ (B).
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CHAPTER 3
AMERICAN GINSENG AND ITS COMPONENTS TREAT COLITIS
IN MICE BY INDUCING NRF2 DEPENDENT ANTIOXIDANT
RESPONSE
ABSTRACT
Ulcerative colitis (UC) is a chronic, inflammatory, bowel disease that affects
millions of people worldwide and increases the risk of development of colon cancer. We
have previously shown that American Ginseng (AG) can treat colitis and prevent colon
cancer in mice. We further fractionated AG and identified the most potent fraction, Hexane
fraction (HAG), and the most potent compound in this fraction, Panaxynol (PA). Oxidative
stress plays a significant role in the initiation and progression of colitis and contributes to
tumorigenesis. Nrf2 is the master regulator of antioxidant response and hence plays an
important role in the resolution of inflammation. To further the understanding of the
mechanism of action of AG and its components, we examined the role of Nrf2 in the
treatment of colitis. We determined the activation of the Nrf2 pathway and relieving
oxidative stress in vitro and in vivo. We also used Nrf2 knockout mice to determine if Nrf2
is essential for AG and its components to operate. We found that AG and its components
activate the Nrf2 pathway and decrease the oxidative stress in macrophages (mФ) and
colon epithelial cells. Consistent with these in vitro results, the Nrf2 pathway is activated
combined with decreased oxidative stress in the DSS-induced colitis mice treated with AG,
HAG or PA. Moreover, these compounds were not effective in the treatment of colitis in
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the absence of Nrf2, when compared to the wild-type mice, further establishing Nrf2 as an
important mediator of AG, HAG, and PA in the treatment of colitis.
3.1 INTRODUCTION
Inflammatory bowel disease (IBD), with rectal bleeding, severe diarrhea, and
weight loss, debilitates approximately 2.6 million people in North America (1), with a
health care cost of more than $3.9 billion annually. The worldwide health care cost is more
than $46 billion annually. Treatment strategies for colitis (and the prevention of colon
cancer) reduce periods of active disease and maintain remission, but outcomes are
marginal. Patients become refractory, and there are dangerous side effects like cancer,
infection, sepsis, hepatitis, and death (2–5). To this end, many colitis patients turn to CAMs
to suppress the disease. 40- 50% of IBD patients use some form of CAM (6,7). Identifying
new treatments that have minimal toxicity to treat the disease and prevent colon cancer,
therefore, remains a high priority.
Previously, we demonstrated that American Ginseng (AG), may be ideally suited
to treat IBD due to its ability to suppress colonic inflammation without apparent toxic side
effects in mice (8–10). In further delineating the active components of AG, a fraction of
AG (AG Fraction V), derived from extraction with n-Hexane as the solvent, was
particularly potent in suppressing colitis and preventing colon cancer in mice (11–13). We
have also seen that PA, an abundant molecule in this fraction suppresses colitis in mice.
The next logical step is to explore the molecular mechanisms of the beneficial effects of
AG and its components on the treatment of UC.
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The etiology of UC remains to be fully elucidated, but involves interactions among
genetic, environmental and immune factors, leading to uncontrolled, abnormal immune
responses in the intestinal mucosa (14). Chronic intestinal inflammation is associated with
enhanced RNOS production, and the consequent oxidative stress plays a critical role in the
pathophysiology of IBD in both animals and humans. For example, elevated RNOS
(reactive oxygen and nitrogen species) formation in colonic mucosa occurs at an early stage
of IBD and correlates with the disease severity (15–17). Prevention of IBD has been shown
by transgenic overexpression of endogenous antioxidant genes and administration of
antioxidant compounds (18–21).
Nuclear factor E2-related factor 2 (NRF2), a master regulator of antioxidant
response element, is a member of the cap'n collar family of basic region-leucine zipper
transcription factor(22). As a transcription factor, NRF2 promotes the expression of phase
II antioxidant enzymes that include, but not limited to, NAD(P)H quinone oxidoreductase1 (NQO1), heme oxygenase-1 (HO-1), glutamate cysteine ligase (GCL), glutathione Stransferase (GST), and glutathione peroxidase (GPx), which all protect against reactive
nitrogen and oxygen species (RNOS). The precise mechanisms of Nrf2 activation are not
fully understood, but it is widely accepted that Keap1 is a key regulator of Nrf2 (23–25).
Nrf2 is normally associated with Keap1 that serves as an adaptor for the interaction of the
Cul3-based E3-ubiquitin ligase complex with Nrf2 leading to Nrf2 ubiquitination then
proteasomal degradation (26). With various stresses or ARE inducers, the system is
perturbed, and Nrf2 escapes from Keap1-mediated ubiquitination, accumulates in the
nucleus, leading to increased Nrf2 target gene transcription(26). Several and probably
overlapping mechanisms for Nrf2 nuclear accumulation in response to oxidative stress or
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inducers like a direct modification of cysteine (Cys) residues of Keap1, Nrf2
phosphorylation of Nrf2, etc. (27–29).
With Nrf2 being an important initiator of antioxidant response required for the
treatment of UC, it is reasonable to hypothesize Nrf2 plays an important role in the
mechanism of action of AG, HAG, and PA. Here, we have shown that AG and its
components (HAG and PA) suppress oxidative stress via activating Nrf2, a key endogenous
regulator of antioxidant defenses, both in vitro and in vivo. We have also demonstrated that
AG and its components suppress colitis by activation of the Nrf2 pathway. We used Nrf2
knockout mice to demonstrate that AG and its components are ineffective in treating colitis
in the absence of Nrf2.
3.2 MATERIALS AND METHODS
3.2.1 CELL CULTURE
All cell lines were maintained in cell culture media supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin and were kept at 37°C in a humidified incubator
with 5% CO₂. ANA-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM,
Hyclone, Logan, UT) and HCT-116 cells were cultured in Roswell Park Memorial Institute
(RPMI)-1640 media. ANA-1 cells were activated by treatment with 10 ng/ml interferon
(IFN)-γ (R&D Systems, Minneapolis, MN) for 8 hours. AG/HAG/PA was dissolved in
media and incubated with cells at specified concentrations for indicated times. For coculture experiments, HCT-116 cells were plated in 6-well dishes and twice the number of
activated ANA-1 cells were placed in the transwell inserts (cat # 2018-11, Grenier bio-one;
Kremsmünster, Austria) to facilitate the exchange of cytokines and other cellular
secretions.
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3.2.2 TOS DETECTION:
ANA-1 mФ were pre-treated with AG, HAG or PA for 12 hours in 6-well dishes.
The media was replaced with media containing IFN-γ (10 ng/ml), and the cells were treated
for 1 hour, 2 hours and 3 hours and processed according to the instructions of the
Superoxide/TOS Chemiluminescent kit (lot # 101214A; Applied Bioanalytical labs.
Briefly, the cells were washed with PBS and resuspended in Hanks’s buffered saline
solution (HBSS). Luminol and enhancer solutions were added before measuring the
luminescence in a luminometer at 425nm. Luminometer quantifies an oxidative burst
through the reaction of luminol with reactive oxygen species to produce a luminophore.
Luminescence

intensity

is

proportional

to

the

number

of

reactive

species

in the sample and is quantified as relative light units.
3.2.3 WESTERN BLOT:
The primary antibodies, HO- 1 (ab13248; Abcam, Cambridge, UK) and GAPDH
(5174S; Cell Signaling, Danvers, MA) were diluted to 1:1000 and incubated with the
membrane overnight at 40C. Horseradish peroxidase-conjugated anti-rabbit secondary
antibody (7074S; Cell Signaling, Danvers, MA) at 1:2000 dilution was incubated at room
temperature for 1 hour. The Western blot signal was detected by Pierce ECL Western
Blotting Substrate (Thermo Scientific, Rockford, IL) and imaged using Bio-Rad
ChemiDoc Imager.
3.2.4 IMMUNOFLUORESCENCE:
Cells (5x105/well) were seeded into six well plates containing a coverslip. The next day,
cells were rinsed with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at
room temperature, followed by permeabilization with 0.1% Sodium Citrate with 0.1%
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Triton X-100. The cells were incubated with Nrf2 antibody at 1:1000 dilution (12721S;
Cell Signaling, Danvers, MA) for one hour at room temperature. The cells were then
washed with cold PBS three times (5 minutes each), and incubated with Alexa 514labeled anti-rabbit secondary antibody (1:1000) (Invitrogen) at room temperature for 1
hour. The cells were then incubated with conjugated actin antibody for 15 minutes. After
washing with PBS, the coverslips were mounted onto the slides with ProLong™ Diamond
Antifade Mountant with DAPI (P36962; Thermo Fisher Scientific). The cells were
examined by fluorescence microscopy (Olympus America Inc, Center Valley, PA).
Fluorescence intensities from images of six randomly selected microscopic fields
of cells were semi-quantitatively analyzed by densitometry (ImageJ software, NIH)
3.2.5 IMMUNOHISTOCHEMISTRY:
For immunohistochemical staining, serial sections of mouse colon tissues
(processed as described above) were incubated with anti-HO-1 (ab13248; Rabbit
Polyclonal, diluted 1:2000; Abcam, Cambridge,UK), 4-Hydroxynonenal (4-HNE)
(ab46545; Rabbit Polyclonal, diluted 1:1000;Abcam, Cambridge, MA), and COX2 (Rabbit
Polyclonal, diluted 1:1000cat # 60126; Cayman Chemical Company, Ann Arbor,MI). To
ensure even staining and reproducibility, sections were incubated by slow rocking
overnight in primary antibodies (4°C) using the Antibody Amplifier™ (ProHisto, LLC,
Columbia, SC).Sections were processed with EnVision+ System-HRP kit according to kit
protocols(K4011; Dako Cytomation, Carpinteria, CA). Immunohistochemistry was
quantified as described previously (11).
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3.2.6 RNA ISOLATION AND RT Q-PCR
The cells were lysed using Trizol and RNA was isolated using the RNeasy mini kit
(Cat # 74104; Qiagen, Hilden, Germany) according to the instructions. RNA
concentrations were measured using NanoDrop 2000 spectrophotometer (Thermo Fisher
Scientific). 1μg of RNA was used for cDNA synthesis using iScript cDNA synthesis kit
(cat # 1708890; Bio-rad, Hercules, CA). The final product was diluted 1:10 for qPCR.
qPCR was performed using iTaq™ Universal SYBR® Green Supermix (cat #1725121;
Bio-rad, Hercules, CA). The list of primers used is as follows in the order forward then
–

HO-1:

AAGCCGAGAATGCTGAGTTCA,

GCCGTGTAGATATGGTACAAGGA;

NQO1:

AGGATGGGAGGTACTCGAATC,

reverse

in

5`-3`

orientation.

AGGCGTCCTTCCTTATATGCTA;

Nrf2:

TCTTGGAGTAAGTCGAGAAGTGT,

GTTGAAACTGAGCGAAAAAGGC; GAPDH: AGGTCGGTGTGAACGGATTTG,
–

HO-1:

CCACCTGTTAATGACCTTGCC,

CACCGGACAAAGTTCATGGC;

NQO1:

GAGGCCAAATCAGGCTTACGG,

CACTCCTGTCCACCAATCGC;

TGTAGACCATGTAGTTGAGGTCA.

AATCCCATCACCATCTTCCA,

Human

primers

TGGACTCCACGACGTACTCA.

GAPDH:
qPCR

was

performed on CFX384 Touch™ Real-Time PCR Detection System (cat # 1855485; Biorad, Hercules, CA).
3.2.7 DSS-INDUCED COLITIS MOUSE MODEL
C57BL/6 and Nfe2l2tm1Ywk were obtained from The Jackson Laboratory. All
mice were on an AIN93M diet as described previously. The mice were either given water
ad libitum or 2% DSS for two weeks, starting on day 0. Treatments with AG (75
mg/kg/day), HAG (75 mg/kg/day) and PA (1mg/kg/day), dissolved in PBS, were carried
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out by oral gavage from day 7-13. The control groups were treated with 1x PBS by oral
gavage as well. All procedures performed were in accordance with the Guide for Care and
Use of laboratory animals (National Research Council, Washington, DC) and by the
approval of the Animal Resource Facility, University of South Carolina, Institutional
Animal Care and Use Committee. On the day of the sacrifice, stool consistency (0-fully
formed stool; 2-loose stool; 4-diarrhea) and blood in the stool (0-no blood; 2-detected using
Hemoccult; 4-rectal bleeding) were scored, and these measurements were used along with
the weight difference in mice from the beginning to the end of the experiment (0=no weight
loss; 1= 0-5% weight loss; 2= 6-10% weight loss; 3=11-15% weight loss; 4=16-20%
weight loss), to calculate the CDI. Blood in stool was detected using Hemoccult (Beckman
Coulter) fecal immunochemical test. Mice were sacrificed on day 14 and colons were fixed
overnight in formalin after they were cut longitudinally and their lengths were measured.
The colons were then embedded in paraffin for sectioning.
3.2.8 INFLAMMATION SCORING
Paraffin-embedded colons were serially sectioned (5 µm), and one section from each
mouse was stained with hematoxylin and eosin (H&E). The stained slides were blindly
examined under a microscope by two investigators (A. Chaparala and A. Chumanevich)
for histopathological changes and scored according to a system previously described
(12,24,25). Briefly, the histology score for inflammation accounts for four parameters – 1)
inflammation severity (0 (no inflammation), 1 (minimal), 2 (moderate), and 3 (severe)); 2)
inflammation extent (0 (no inflammation), 1 (mucosa only), 2 (mucosa and submucosa),
and 3 (transmural)); 3) crypt damage (0 (no crypt damage), 1 (one-third of crypt damaged),
2 (two-thirds damaged), 3 (crypts lost and surface epithelium intact), and 4 (crypts lost and
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surface epithelium lost)) and; 4) percentage area of involvement (0 (0% involvement), 1
(1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%)). The scores for the first three
parameters are added, and the sum is multiplied by the fourth parameter, giving a range of
scores between 0-40.
3.2.9 STATISTICAL ANALYSIS
Data are expressed as a mean ± standard error of the mean. Mean differences
between the groups were compared by one-way analysis of variance (ANOVA), followed
by Dunnett’s multiple comparison tests. A P-value of ≤ 0.05 was chosen for significance.
3.3 RESULTS
3.3.1 AMERICAN GINSENG

AND ITS DERIVATIVES ACTIVATE

NRF2

PATHWAY IN

MACROPHAGES

We have previously shown that American Ginseng decreases total oxygen species
in mФ activated to M1 type by IFN-γ. Here, we show that ANA-1 cells pre-treated with
HAG and PA also show decreased total oxygen species when stimulated with IFN-γ
(Figure 3.1 G). Antioxidant response mediated by Nrf2 is the most important phenomenon
that is responsible for defense against inflammation. We hypothesize that American
Ginseng and its components, HAG and PA decrease the reactive oxygen species by
activating the antioxidant response via Nrf2. To test this hypothesis, we looked at the
translocation of Nrf2 into the nucleus as well as activation of a key target gene activated
by this transcription factor. Immunofluorescence data shows that Nrf2 is localized to the
nucleus upon treatment with AG, HAG or PA, indicating its activation (Figure 3.3A). HO1, a target of Nrf2, is upregulated by AG, HAG and PA treatment of ANA-1 mФ, as shown
by immunoblot and qPCR and immunoblot (Figure 3.3 B, D). Nrf2 has two ARE elements
in its promoter region, and the elevated expression of Nrf2 gene indicates self-activation,
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as seen in Figure 3.3C. To check the activation of Nrf2 in epithelial cells in an inflammatory
environment, we co-cultured HCT-116 cells with activated ANA-1 cells for 3 hours. RTqPCR data indicates that Nrf2 and HO-1 show increased expression when HCT-116 cells
were pre-treated with AG, HAG, or PA (Figures 3.3 E, F).
3.3.2 AMERICAN GINSENG

AND ITS DERIVATIVES SUPPRESS OXIDATIVE STRESS AND

ACTIVATE NRF2 PATHWAY IN VIVO

To evaluate if Nrf2 is activated by the AG, HAG, and PA in vivo, we used DSS
induced colitis mouse model. We used previously tested doses of AG (75 mg/kg/day),
HAG (75 mg/kg/day) and PA (1 mg/kg/day) to treat mice by oral gavage. The colons were
probed for 4-hydroxy-2-nonenal (4HNE) and HO-1. 4HNE is a product of lipid
peroxidation and a biomarker for cellular oxidative stress; and HO-1, as indicated above,
is a target of Nrf2. We see the decreased expression of 4HNE in the treatment groups
indicating reduced oxidative stress (Figures 3.2A, B). We also see increased expression of
the HO-1 protein, indicating the activation of the Nrf2 pathway (Figures 3.2C, D).
3.3.3 AMERICAN GINSENG AND ITS DERIVATIVES

SUPPRESS COLITIS BY ACTIVATING

NRF2

PATHWAY

We have previously shown that AG, HAG, and PA suppress DSS induced colitis in
mice. Nrf2 activation is important for the antioxidant response, which in turn is important
for defense against inflammation caused by ulcerative colitis. Since AG and its derivatives
activate Nrf2 pathway in vitro and in vivo, we hypothesized that their mechanism of action
requires activation of Nrf2 mediated anti-oxidant response. To test this hypothesis, we
compared the effectiveness of AG, HAG, and PA in the treatment of DSS induced colitis
in wild-type with that of their effectiveness in Nrf2 knockout mice. We used the previously
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described 14-day DSS induced colitis mouse experiment (Figures 3.3A, B). AG, HAG, and
PA lowered the CDI in wild-type mice but not in the Nrf2 knockout mice (Figure 3.3 C).
We scored inflammation as indicated by ulceration, damage to crypts, and infiltration by
inflammatory cells, using H and E slides of colon sections. Treated wild-type mice had
significantly lower histology score than DSS-only mice, while the treatment was not as
effective in case of Nrf2 knockout mice (Figures 3.4 A, B). We also tested
immunoreactivity of COX2, a proinflammatory enzyme that has elevated protein
expression during inflammation. We see that AG, HAG, and PA effectively decrease COX2 expression in wild-type mice, but not the Nrf2-/- mice (Figures 3.4 C, D). Put together,
this confirms that AG and its derivatives treat DSS induced colitis in mice by activating
the Nrf2 pathway.
3.4 DISCUSSION
Deregulation of intestinal immune responses is considered a major contributor to
IBD; the mechanisms of which are not well understood. A better understanding of this
phenomenon would lead to better treatment strategies and would help millions of people,
and reduce the tremendous cost of treatment with small synthetic molecules. Because IBD
(aka colitis) is, by definition, chronic colon inflammation, it is reasonable that antioxidantbased approaches have shown efficacy in treating IBD (30). Current FDA-approved
therapies involve treatment with 5-aminosalicylic acid (5-ASA) and its analogs, as well as
glucocorticosteroids and anti-TNFα biologicals. Such treatment reduces periods of active
disease and helps to maintain remission. Although these drugs have modest beneficial
effects, patients become refractory, and there are significant side effects (31). This
underscores the importance of developing more effective IBD therapies. To this effect, we
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have explored the potency of a natural compound, AG in the treatment of colitis and
identified the bioactive components that could be responsible for AG’s efficacy. The
identification of a single, active component would bring AG a step closer to being used as
a mainstream medicine. In this context, it makes sense and would be significant to explore
the molecular mechanisms of AG-mediated beneficial effects on the treatment of IBD.
An increased susceptibility also shows a key role of endogenous antioxidants in controlling
intestinal inflammatory stress to chemically induced IBD and associated colon cancer in
Nrf2-/- mice (32,33). As Nrf2 is a central regulator of tissue antioxidant defenses (23),
these studies not only support a causative role of oxidative stress in IBD but also suggest
that targeting Nrf2 provides a novel antioxidant-based intervention of IBD and the
chemoprevention of colon cancer. AG and other plant products like resveratrol have been
shown to combat cellular stress by activating the antioxidant mechanisms in the cell.
Korean ginseng has been shown to activate Nrf2 pathway (34,35), and we have previously
demonstrated with our collaborators that AG can activate Nrf2 in cardiomyocytes (36).
Since AG and HAG are anti-inflammatory and suppress many of the molecular targets of
Nrf2 (9–12,37,38), it is reasonable that Nrf2 is at the crossroads of the protective effects of
AG/HAG/PA, and colitis-associated carcinogenesis. Nrf2 mediated antioxidant response
plays an important role in resolving inflammatory diseases and could play an important
role in AG mediated treatment of colitis.
In this study, we measured the antioxidant response and activation of Nrf2 signaling
pathway upon treatment with AG and its components, macrophage cell lines (in vitro), and
mouse colon (in vivo). Treatment with AG, HAG, and PA activated HO-1 in ANA-1
macrophage cell lines and mouse colons with DSS induced colitis. They also induced the
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translocation of Nrf2 into the nucleus, indicating its activation. Furthermore, we saw that
these treatments also decreased the production of TOS in vitro, and the expression of 4HNE
in vivo indicated decreased oxidative stress. Upon confirming that AG and its components
activate Nrf2 pathway, we used Nrf2 -/- mice to investigate if the Nrf2 pathway is essential
for the treatment of colitis. As predicted, AG and its components were not very effective
in the Nrf2-/- mice as evidenced by the inflammation scores and expression of COX2.
Though the effects of AG and its components have been diminished considerably,
there is still a decrease in inflammation with AG treatment of Nrf2 -/- mice. This could be
due to the effect of p53, which also plays an important role in the activation of antioxidant
mechanisms like the synthesis of GSH and NADPH generation (39,40). We have
previously shown that the mechanism of action of AG in the treatment of colitis is p53
dependent, but the mechanism of HAG is only partially dependent on p53 (10,12). Apart
from possessing antioxidant properties, Nrf2 has also been shown to negatively regulate
the expression of pro-inflammatory genes that are induced in M1 mФ (41). This is
consistent with the decreased expression of ROS, a proinflammatory marker, and could be
an additional mechanism by which Nrf2 activation helps in the treatment of colitis, that we
would explore in the future.
AG, HAG, and PA caused a decrease in the expression of Histone Deacetylase 1
(HDAC-1) and DNMT-1 in ANA-1 mФ (Figure A1). The increase in Nrf2 shown in Fig.
8B at the same time as a decrease in HDAC-1 and DNMT-1 is consistent with the
hypothesis that these enzymes may regulate nrf2 expression. The AG fraction also downregulates the expression of miR-142 (Fig. 9) (13), known to target Nrf2 (42), thereby
suggesting that AG may increase Nrf2 through down-regulation of miR-142. Because Nrf2
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is involved in colitis and associated colon cancer (32,33,43–45), we believe it would be of
significance to examine the ability of AG, HAG, and PA to target Nrf2 as a mechanism for
the protection of colitis and colon cancer. Such studies will not only better elucidate the
mechanisms by which AG, HAG, and PA work in this disease, but also: (1) identify other
diseases where Nrf2 is dysregulated that AG, AG-Fraction V, and individual constituents
may be beneficial [e.g., obesity (46), neurodegenerative diseases (47), vascular diseases
and aging (48), cardiovascular disease (23), and diabetes (49)]; (2) identify other CAMs or
small molecules that target Nrf2 that may be beneficial to patients with colitis at a high
colon cancer risk [e.g., triterpenoids that target Nrf2 also suppress experimental colitis
(50,51)]; and (3) identify epigenetic biomarkers of Nrf2 regulation and attenuation of
inflammation.
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Figure 3.1: AG, HAG, and PA activate Nrf2 pathway and decrease ROS in vitro. A)
AG, HAG, and PA induce translocation of Nrf2 into the nucleus. ANA-1 cells were treated
with AG (100 μg/ml), HAG (100 μg/ml) and PA (1 μM) for 8 hours. Representative images
of immunofluorescence (n=3). Green arrows indicate nuclei with Nrf2 expression. B) AG,
HAG, and PA increase the expression of HO-1. Western blot image of ANA-1 cells treated
with indicated doses of AG, HAG, and PA for 8 hours. C, D) AG (100 μg/ml), HAG (100
μg/ml) and PA (1 μM) increase the expression of HO-1 (C) and NQO1 (D) in ANA-1 cells.
RT-qPCR data is cumulative of three separate experiments. E, F) AG, HAG and PA
activate Nrf2 pathway in HCT-116 cells in the presence of activated mФ. HCT-116 cells
were pretreated with AG (100 μg/ml), HAG (100 μg/ml) and PA (1 μM) and co-cultured
with activated ANA-1 (10 ng/ml IFNγ) for 3 hours and separated for qPCR. P-values - * >0.05, ** - >0.005, *** - >0.001, **** - >0.0001. Values represent the mean ± S.D. The
significance is compared with the DSS only group. G) An oxidative burst in ANA-1 mouse
mФ is suppressed by pretreatment with AG (100 μg/ml), HAG (100 μg/ml) and PA (1 μM).
The protocol described in methods.
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Figure 3.2: AG, HAG, and PA activate Nrf2 pathway and decrease ROS in vivo. Effect
of AG, HAG, and PA on oxidative stress and Nrf2 pathway activation. DSS-induced colitis
mice were treated with AG (75 mg/kg/day), HAG (75 mg/kg/day), or PA (1 mg/kg/day).
Colons from these mice were probed for A, B) 4-HNE and C, D) HO-1 to indicate oxidative
stress and Nrf2 pathway activation, respectively. Values represent the mean ± S.E. N= 8.
The significance is compared with the DSS only group. P-values - * - >0.05, ** - >0.005.
A and C are representative images (400X magnification)
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Figure 3.3 AG, HAG, and PA decrease the CDI in WT mice but not Nrf2 -/- mice. A,
B) Schematic and groups of the experiment. C) Effect of AG (75 mg/kg/day), HAG (75
mg/kg/day) and PA (1 mg/kg/day) on the clinical disease index which accounts for weight
loss, blood in stool and stool consistency. Values represent the mean ± S.E. Significance is
compared with the DSS only sub-group within WT and Nrf2 -/- groups. P-values - * >0.05, ** - >0.005, *** - >0.001, **** - >0.0001.
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Figure 3.4 AG, HAG, and PA decrease the inflammation in WT mice but not Nrf2 -/mice. Seven-ten mice from each group from Fig 3.3 were euthanized on day 14, and colons
were harvested. A, B) Effects of AG, HAG, and PA on the colon histology score in the
acute DSS colitis model. The histology score was determined as discussed in Materials
and methods. Values represent the mean ± S.E. of the mean. Representative H&E-stained
colons are shown for each group (A). Sections of the colon were probed for COX2. C)
Representative images. D) Immunoreactivity score. *Significant difference from the DSS
group (P values * - >0.05, ** - >0.005, *** - >0.001, **** - >0.0001.).
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Figure 3.5 AG, HAG, and PA suppress colitis by activation of the Nrf2 pathway.
Schematic representing the conclusions - oxidative stress is one of the factors that play a
significant role in the progression of colitis. AG, HAG, and PA activate the transcription
factor, Nrf2, which in turn activates antioxidant genes that decrease oxidative stress,
thereby suppressing colitis.
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CHAPTER 4
GENE EXPRESSION PROFILING OF PRIMARY PERITONEAL
MACROPHAGES TREATED BY AMERICAN GINSENG
ABSTRACT
Ginseng has been widely used for its beneficial effects on the general health as well
as its medicinal properties in the treatment of various ailments. We have previously shown
that American Ginseng (AG) and its components suppress ulcerative colitis (UC) in mouse,
underscoring their anti-inflammatory properties, especially in the macrophages (mФ).
However, the immunostimulatory effects of AG on the innate immune system in the
absence of inflammation are unclear. MФ play an important role in the initiation of innate
immune response and activation of the adaptive immune system. To elucidate the various
key players in the mechanism of action of AG and understand the effects of AG on the
immune system in a normal state without any inflammation, we conducted a microarray
experiment using primary peritoneal mФ isolated from mouse and treated with AG or one
of its derivatives. Microarray analysis revealed that treatment with AG increases the
expression of various proinflammatory pathways, as seen by the increased expression of
proinflammatory cytokines like IL6, IL-1α, IL-1β, CXCL1, CXCL3, and CXCL5. This
suggests that AG and its components stimulate the immune system to prime it against
possible infection and any other environmental or endogenous insults to the body and this
property of AG can establish it as an adjuvant therapy.
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4.1 INTRODUCTION
Korean Ginseng is one of the most-used herbal medicines in the East. More
recently, other types of ginseng, such as American Ginseng (AG) have been used as
alternative medicines worldwide, due to their immunosuppressant, anti-tumorigenic,
hypoglycemic, antioxidant, and anti-depressant effects (1–3). Furthermore, patients
suffering from chronic inflammatory diseases use AG in the remission state between the
flare-ups. Consistent with this, we have previously studied the immunosuppressive effects
of AG in an inflammatory environment and found that AG and its components (a Hexane
Fraction of AG, or HAG; and panaxynol, or PA) act as anti-inflammatory agents (4,5)(
Chapters 2 and 3 of this dissertation). To better understand the underpinnings associated
with the mechanisms by which AG, HAG, and PA suppress colitis and prevent colon
cancer, we used gene expression profiling of primary peritoneal mФ (PPMs) by microarray
and validated the genes with significant increase in expression upon treatment, with qPCR.
We found that treatment with AG increases the expression of cytokines [interleukin
(IL)-1α, IL-1β, IL-6, and COX-2] and chemokines [chemokine (C-X-C motif) ligand
(CXCL)-1, CXCL3 and CXCL5. PA, the bioactive component of AG, also upregulated the
expression of IL-1α, CXCL1, and CXCL5; while HAG activated IL-1α and CXCL5. These
results indicate that AG and its components can act as stimulants of a resting immune
system.
4.2 MATERIALS AND METHODS
4.2.1 ISOLATION AND TREATMENT OF PRIMARY PERITONEAL MACROPHAGES
Primary peritoneal mФ (PPMs) were harvested from 8-10 week old C57Bl/6 mice.
Mice were anesthetized and sacrificed by cervical dislocation. 8 ml of phosphate buffer
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saline (PBS) with 5% fetal bovine serum (FBS) was injected into the peritoneal cavity
using a 10-gauge syringe, and the peritoneal cavity was massaged to dislodge the immune
cells in the cavity. The PBS is aspirated back and spun at 1000 RPM for 10 minutes, and
the pellet is resuspended in RPMI media containing 5% FBS. Cells from one mouse were
plated in one well in a 6-well dish to be used as a biological replicate. Cells were incubated
for 2 hours at 370 C and 5% CO2 and supernatant is aspirated, and the wells were washed
with PBS. The attached cells are mostly mФ and are incubated in whole RPMI media
containing 50 μg/ml mouse macrophage colony stimulating (mM-CSF) factor overnight.
The media was aspirated, and the cells were treated with 250 mg/ml AG in whole media
with mM-CSF.
4.2.2 RNA ISOLATION AND QUANTIFICATION
Total RNA was isolated using the Qiagen RNeasy Plus Micro Kit according to the
manufacturer’s protocol. RNA concentration was measured using Nanodrop 2000. RNA
quality was assessed using an Agilent 2100 Bioanalyzer, and RNA Integrity Numbers
ranged from 9.8 to 10.0.
4.2.3 MICROARRAY ANALYSIS
Microarray experiments were performed using Affymetrix’s platform. Total RNA
samples were amplified and biotinylated using GeneChip WT PLUS Reagent Kit
(Affymetrix, Santa Clara, CA). Briefly, 100 ng of total RNA per sample was reverse
transcribed into ds-cDNA using NNN random primers containing a T7 RNA polymerase
promoter sequence. T7 RNA polymerase was then added to cDNA samples to amplify
RNA, and then RNA was copied to ss-cDNA and degraded using RNase H. ss-cDNA
molecules were then fragmented and terminally labeled with biotin. Amplified and labeled
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samples were hybridized to MoGene-2_0-st (Affymetrix, Santa Clara, CA) for 16 h at 45°C
using a GeneChip Hybridization Oven 640 and a GeneChip Hybridization, Wash, and Stain
Kit (Affymetrix, Santa Clara, CA). Hybridized arrays were washed and stained using
GeneChip Fluidics Stations 450 (Affymetrix, Santa Clara, CA). Arrays (6 total) were then
scanned using a GeneChip Scanner 3000 7G system and computer workstation equipped
with GeneChip Command Console 4.0 software (Affymetrix, Santa Clara, CA).
4.2.4 REVERSE TRANSCRIPTASE-QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR)
The cells were lysed using Trizol and RNA was isolated using the RNeasy mini kit
(Cat # 74104; Qiagen, Hilden, Germany) according to the instructions. RNA
concentrations were measured using NanoDrop 2000 spectrophotometer (Thermo Fisher
Scientific). 1μg of RNA was used for cDNA synthesis using iScript cDNA synthesis kit
(cat # 1708890; Bio-rad, Hercules, CA). The final product was diluted 1:10 for qPCR.
qPCR was performed using iTaq™ Universal SYBR® Green Supermix (cat #1725121;
Bio-rad, Hercules, CA). The list of primers used is as follows in the order forward then
–

HO-1:

AAGCCGAGAATGCTGAGTTCA,

GCCGTGTAGATATGGTACAAGGA;

NQO1:

AGGATGGGAGGTACTCGAATC,

GAPDH:

AGGTCGGTGTGAACGGATTTG,

IL6:

CCAAGAGGTGAGTGCTTCCC,

reverse

in

5`-3`

orientation.

AGGCGTCCTTCCTTATATGCTA;
TGTAGACCATGTAGTTGAGGTCA.,
CTGTTGTTCAGACTCTCTCCCT;

CXCL3:

TAACCCTCATCAGAGTACTGGC,

GAAAGAGGCTCCAGGTAGGG;

CXCL1:

TGAGCTGCGCTGTCAGTGCCT,

AGAAGCCAGCGTTCACCAGA;

CXCL5:

CCTCCTTCTGGTTTTTCAGTTTAGC;
TGAGTCACAGAGGATGGGCTC;

GCATTTCTGTTGCTGTTCACGCTG,

IL-1b,

IL-1a:

85

CCTTCCAGGATGAGGACATGA,
CGAAGACTACAGTTCTGCCATT,

GACGTTTCAGAGGTTCTCAGAG;

Ptgs2:

TGCCTGGTCTGATGATGTATG,

GCCCTTCACGTTATTGCAGATG. qPCR was performed on CFX384 Touch™ RealTime PCR Detection System (cat # 1855485; Bio-rad, Hercules, CA).
4.2.5 STATISTICAL ANALYSIS
Following completion of array scans, probe cell intensity (CEL) files were imported
into Expression Console Software (Affymetrix, Santa Clara, CA) and processed at the
gene-level using the Robust Multichip Analysis (RMA) algorithm to generate CHP files.
After confirming data quality within Expression Console, CHP files containing log2
expression signals for each probe were then imported into Transcriptome Analysis Console
Software version 4.0 (Affymetrix, Santa Clara, CA) to analyze cell type-specific
transcriptional responses using one-way between-subject analysis of variance (ANOVA).
A p-value of 0.05 and a fold change of 2.0 was used as cutoff parameters. Subsequently,
pathway analysis of the differentially expressed genes was performed using Ingenuity
Pathway Analysis software (IPA) (Qiagen, Hilden, Germany).
qPCR data is expressed as a mean ± standard error of the mean. Mean differences
between the groups were compared by one-way analysis of variance (ANOVA), followed
by Dunnett’s multiple comparison tests. A p-value of ≤ 0.05 was chosen for significance.
4.3 RESULTS
4.3.1 GENE EXPRESSION PROFILE OF PRIMARY PERITONEAL MACROPHAGES

TREATED WITH

AMERICAN GINSENG
PPM isolated from C57B/6 mice were cultured for a day and treated with 250
mg/ml of AG for 8 hours in quadruplicates. RNA collected from these samples was
analyzed for concentration, purity, and integrity, upon which three biological replicates for
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each condition were selected for microarray analysis. We determined the treatment doses
prior to microarray to ensure that these concentrations would cause a change in gene
expression. We accomplished this by probing PPMs treated with various doses of AG,
HAG, and PA, for HO-1, a known target of all three compounds. We compared the treated
and untreated samples using Kruskal-Wallis statistics with Benjamini-Hochberg multiple
testing corrections at a fold-change cut-off of 2 and a p-value of 0.05. The number of
differentially expressed genes with at least 2-fold change were identified. 32 genes were
upregulated, and 20 genes were downregulated upon treatment with AG when compared
to the vehicle group (Figure 4.1A). However, HAG only had one gene that showed more
than 2-fold change in expression and PA did not have any viable target genes that had any
change in expression profile (Figure 4.1A). There was only one common target for AG and
HAG which was NQO1 (Figure 4.1B). Surprisingly, a number of pro-inflammatory genes
were activated by AG. Of these, the expression of IL-6 was elevated the most with the AG
treatment with a fold change of 5.87 and a p-value of 0.0005. Scatter plot of differentially
expressed genes and hierarchal clustering of intensities of mRNA expression are shown in
Figures - 4.2 and 4.3 respectively. The list of genes that are differentially expressed with
AG treatment is presented in Table 4.1.
4.3.2 INGENUITY PATHWAY ANALYSIS (IPA) OF MICROARRAY RESULTS
IPA shows distinct activation of triggering receptor expressed on myeloid cells
(TREM1) signaling pathway, with the target genes CXCL3, IL1B, IL6, NLRP3, and CSF2,
with the first three genes showing more than 2.5 fold increase in gene expression (Figure
4.4). Activation of the TREM1 receptor that is expressed on mФ and neutrophils plays an
important role in systemic infection by causing a cascade of events that result in cytokine
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production. The top- hits like CXCL2, CXCL3, PTGS2, IL1A, IL1B, and IL6 are also
involved in toll-like receptor (TLR) signaling, especially TLR2, TLR3, TLR4, TLR5, and
TLR9. The target genes identified here are upstream regulators of various proinflammatory
genes and play an important role in the recruitment, activation, and migration of
phagocytes, in this case, mФ.
4.3.3 REVERSE TRANSCRIPTASE-QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR)
ANALYSIS OF SELECTED TARGET GENES

To confirm the differential expression of the targets identified in the microarray
analysis, we conducted the RT-qPCR analysis. Since HAG or PA did not yield multiple
results, we validated the targets of AG using qPCR and compared the gene expression in
the samples from HAG and PA. This analysis confirmed the activation of proinflammatory
cytokines by AG. We saw that, while some of AG's targets only showed increased
expression upon AG treatment, e.g., IL6, IL-1β, and CXCL3 (Figure 4.4A, B, C), others
showed changed gene expression profiles in HAG and/or PA. IL-1α and CXCL1 showed
increased expression in both HAG and PA-treated cells (Figures 4.4 D, E), while CXCL5
expression was increased in PA but not HAG (Figure 4.4F).
PTGS2 or COX2, one of the potential targets was not validated by qPCR (Figure
4.4 G). We also examined the expression of NQO1 and HO-1 as they have previously been
shown to be upregulated in AG treatments. NQO1 was also one of the targets of both AG
and HAG that manifested in the microarray analysis. However, there was no change in the
expression with any of the treatments when validated with qPCR. HO-1, on the other hand,
showed increased expression with AG, HAG, or PA treatments, even though it was not one
of the genes with changed expression profile in the microarray (Figure 4.4 I).
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4.4 DISCUSSION
AG has been used as an anti-inflammatory agent for the treatment of UC in our
previous studies (6,7), and we found that PA, a polyacetylene in AG specifically targets
mФ for DNA damage and apoptosis. PA was the most abundant compound in the hexane
fraction of AG (HAG), the most potent of the various fractions of AG (5). To further
understand the mechanisms of action of AG, HAG, and PA in the treatment of colitis and
prevention of colon cancer, we profiled the gene expression patterns in PPMs using
microarray analysis.
Curiously, treatment with AG resulted in the upregulation of a number of cytokines
and chemokines, which is in contrast with their anti-inflammatory properties.
Unfortunately, microarray analysis of treatment with HAG only yielded one gene with an
at least 2-fold change in expression and treatment with PA did not produce any valid
targets, even though we standardized the dose and treatment times prior to the microarray.
However, when we followed up on the top-hits with AG treatment using qPCR in the
samples treated with all three compounds to identify any common targets and targets
unique to AG treatment, we found that HAG and PA also increased the expression of some
of the cytokines and chemokines. This discrepancy in results could be due to the fact that
qPCR is more sensitive and quantitative than microarray.
This immunostimulatory effect of AG could indicate that AG can boost the innate
immune system to prime it against infections and other environmental insults. This
property of AG can also be exploited in cancer immunotherapy for use as an adjuvant. The
immune system is comprised of two separate and interacting components – innate and
adaptive immunity. The innate immune system forms the first barrier of defense against
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the infections and includes physical barriers like skin and mucous membranes; phagocytic
immune cells like mФ and natural killer cells; inflammatory mediators like eosinophil
granules; and cytokines (8,9). These components recognize infection and initiate primary
reactions to prevent and eliminate an infection. Toll-like receptors (TLRs) are pattern
recognition receptors (PPRs) that are present on the myeloid cells like mФ and dendritic
cells, recognize pathogen-associated molecular patterns (PAMPs) on the invading
pathogens and danger associated molecular patterns (DAMPs) from tissue injury, and
initiate an appropriate immune response (10–12). This immunological signaling is finely
balanced. Lack of appropriate regulation of TLRs can result in chronic inflammation
(13,14). Conversely, the decreased response in early stages of infection or neoplastic
transformation can have adverse effects like worsened infection or tumor formation (15).
MФ form an important part of the innate immune system and are activated by binding of
ligands to surface TLRs like TLR4 (16–18). In the presence of an impending infection, mФ
are activated to phagocytose the pathogens and produce proinflammatory cytokines like
TNFα, and inflammatory mediators like nitric oxide (NO) and H2O2 (19). Plant extracts
have been previously shown to modulate the TLR activation and function (20–23).
Among the predicted upstream regulators of the top genes, TLR4 appears to be of
importance. It has been previously shown that plant extracts can initiate an innate immune
response by activating TLRs, particularly TLR4 (20–22). This can result in the activation
of transcription factors like NF-κB and AP-1, which in turn increase the production of
proinflammatory mediators like TNF-α, IL-6, IL-1, and COX2 (24). The activation of
proinflammatory cytokines by AG could be a result of TLR4 activation. TLR agonists are
currently being investigated in the development of immunotherapy strategies for the
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treatment of cancer. TLR ligands have been previously used as adjuvants in the
development

of

vaccines

in

cancer

immunotherapy

(25–27).

For

example,

Monophosphoryl lipid A (MPL), a TLR4 ligand is being tested as an adjuvant to vaccines
against colorectal carcinoma, melanoma, glioma, etc., to initiate tumor-specific immunity
in response to vaccination (28). Adjuvants can decrease the immunotolerance in the tumor
microenvironment and aid in the initiation of anti-tumor response(25,27). If AG is
established as a TLR ligand, it can be used as an adjuvant with vaccines for cancer and
infectious diseases.
We used PPMs, which have not been polarized to either M1 or M2 type in our
study. For future studies, we will confirm the findings above, then compare the effects of
AG and its components between the different types of mФ, in vivo and in vitro by
examining the expression patterns of proinflammatory cytokines. We will also examine the
effects of AG on dendritic cells which along with mФ are the sentinels of innate immune
system and function via TLR signaling. These studies will provide an insight into the
divergent effects of AG, especially in the treatment of UC. UC is a chronic disease with
periods of remission alternated with a period of flare-ups. It is important to have active
immune system in the remission periods to enable the body to fight the infections. The
property of AG to modulate the immune system will be especially appreciated in these
periods of remission to ensure the patient is not susceptible to infections.
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Figure 4.1 Gene expression profiling of primary peritoneal macrophages treated with
AG, HAG, and PA. A) Summary of the microarray analysis of PPMs treated with AG
(100μg/ml), HAG (100μg/ml) and PA (1μM) to address the number of genes that have been
differentially regulated. B) Venn diagram representing common targets that manifested in
microarray analysis.
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Figure 4.2 Representation of differential gene expression with AG treatment when
compared to the control group. Scatter plot of mRNA expression determined by mRNA
microarray analysis. The expression profile of ~35,000 mRNAs on a log2 scale with AG
treatment and control group is plotted. Red and green dots represent the mRNAs that were
significantly (P < 0.05 and 1.5 fold-change cut-off) up-regulated and down-regulated,
respectively, in AG group. Grey dots represent a lack of differential expression.

94

Table 4.1 List of differentially expressing genes with AG treatment
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Figure 4.3 Hierarchal clustering of replicates. Hierarchical clustering of samples based
on differentially expressed genes with at least 2-fold change and controlled by false
discovery rate of 0.1, from AG treated vs. control groups. In the clustering heat map, red
indicates upregulation while green indicates downregulation. In the sample clustering
dendrogram, red indicates AG samples while blue indicates control samples. The intensity
of expression is indicated by blue (low) and red (high), with white being medium.
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Figure 4.4 Activation of TREM pathway from IPA. TREM pathway showed activation
in IPA. TREM pathway involving TLR4 is upstream of the cytokines and chemokines that
were upregulated by AG.One of the TREM pathways, involving proinflammatory response
is highlighted here.
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Figure 4.5 Validation of differentially expressed genes by qPCR. Targets identified by
microarray analysis of AG treated mФ was validated in all three treatments. A, B, C) Genes
that were validated only in AG. D, E, F) Genes also verified in HAG and or PA. G, H)
Identified targets of AG that were not validated by qPCR. Fold changes presented are
cumulative mean of three separate experiments.
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CHAPTER 5
CONCLUSION AND FUTURE DIRECTIONS
5.1 SUMMARY AND CONCLUSIONS
American Ginseng (AG), and one of its fractions, HAG, have been shown to be
effective in the treatment of colitis and colon cancer in mice. In chapter 2, we aimed to
identify the bioactive component of AG. We used bioassay-guided fractionation to isolate
various sub-fractions of HAG and test their ability to suppress the expression of iNOS, an
inflammatory marker. PA was the most abundant compound in the fraction with the antiinflammatory potential and was further studied as a potential treatment for colitis. PA
successfully suppressed DSS-induced colitis in the mouse. We also found that PA
selectively targets macrophages (mФ) for apoptosis in vivo and in vitro. Additionally, PA
was more effective than clodronate, a compound that specifically targets mФ and did not
enhance the effect of clodronate in the treatment of colitis. However, PA was not effective
in the prevention of colitis.
In chapter 3, we explore the mechanism of action of AG, HAG, and PA. We have
previously seen that AG decreases oxidative stress in proinflammatory mФ. Here we see
that HAG and PA decrease the production of ROS and thereby oxidative stress in the mФ.
AG, HAG, and PA also activate the Nrf2 dependent antioxidant pathway in both ANA-1
and HCT-116 cells that were co-cultured with ANA-1 cells. These components also
activate Nrf2 pathway and decrease oxidative stress in vivo in DSS-induced colitis colons.
In the absence of Nrf2, AG and its components are not very effective in the treatment of
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colitis as seen by the comparison between wild-type and Nrf2 knockout mice. However,
even in the absence of Nrf2, AG slightly decreased the extent of colitis. This could be due
to the role that p53 plays in the treatment of colitis by AG.
In chapter 5, we wanted to further explore the effect of AG on the innate immune
system. We conducted a gene expression profiling of primary peritoneal mФ treated with
AG using microarray. Surprisingly, the gene expression profile indicated that AG increased
the expression of proinflammatory cytokines like IL-1α, IL-1β, and IL-6 and chemokines
like CXCL2, CXCL3, and CXCL5. We confirmed the top hits of microarray using RTqPCR in AG samples, as well as HAG and PA samples. The pathway analysis of these
targets and other genes with increased expression indicated that proinflammatory pathways
like NFκb and TNF-α pathways could be activated. This contradicts with the antiinflammatory activity of AG in the treatment of inflammatory diseases. However, this
indicates that AG can act as an immune boost to prime the immune system to fight potential
infections
From the findings in this dissertation, we have identified the bioactive component
of AG and gained insights into the mechanism of action of AG and its components. PA
treats colitis in mice by the selective targeting of mФ for DNA damage and apoptosis.
Activation of the Nrf2 antioxidant mechanism is the key to the mechanism of action of AG,
HAG, and PA. Activation of proinflammatory pathways by AG in a normal state provides
insight into the immunomodulatory effects of AG and provides a segue for future
investigations.
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5.2 FUTURE DIRECTIONS
To further the outcomes from chapter 4, we will compare the expression of
proinflammatory cytokines and activation of proinflammatory pathways between activated
and non-activated mФ in vitro using primary cells and established cell lines. In vivo, we
will study the effect of treatment with AG on the innate immunity in the absence of an
infection. This will help us understand its effectiveness in the prevention of infections.
We would like to explore further, the mechanism by which PA targets mФ. Since
PA causes DNA damage, we will concentrate on DNA repair pathways that could be
impaired in the mФ, leading to apoptosis. Identifying the DNA repair mechanism and its
status in non-macrophage cell lines would provide understanding into the specificity of PA
in targeting the mФ.
We will test the toxicity and side effects of PA in the organs collected during our
in vivo experiments (e.g., Liver: Serum Bilirubin, Serum Albumin, ALT [Alanine amino
transferase], and AST [Aspartate amino transferase] test; Kidney: Urinalysis, Blood Urea
nitrogen). Upon validation of PA as a safe and effective treatment for colitis in classic
models of IBD, we hope to explore its potential as a treatment for other inflammatory
diseases like rheumatoid arthritis, lupus, and psoriasis, improving the quality of life for
millions of people.
Since colitis increases the risk of colitis-associated colon cancer, we conducted
preliminary studies to determine the effectiveness of PA in the prevention of colon cancer.
These studies conducted with AOM-DSS mouse model showed that PA-treated mice had
smaller tumors (> 2mm). Preliminary data also indicates that PA decreases the expression
of DNMT1 and HDAC in activated ANA-1 cells, indicating its role in epigenetic regulation
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(Figure A.1). We will explore the possibility of PA as a chemopreventive agent for colon
cancer using various colon cancer mouse models with an emphasis on epigenetics.
We will also study other components of AG in the hexane fraction, mainly
polyacetylenes like Panaxydol and Panaxadiol.
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APPENDIX A.
EPIGENETIC EFFECTS OF AMERICAN GINSENG AND ITS
COMPONENTS
A.

B.

C.

Figure A.1 AG, HAG, and Panaxynol decrease the expression of DNMT-1 and
HDAC1 in stimulated ANA-1 cells. ANA-1 cells were pretreated with AG (250 µg/ml),
HAG (10 µg/ml), or Panaxynol (5 µM), followed by stimulation with IFN-γ (10 ng/ml) for
indicated times.
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